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ABSTRACT
Rogers, Tiffany Danielle. Ph.D. The University of Memphis. August 2012. Evaluation of
Cerebellar-Cortical Circuitry Using Rodent Models: Relevance to Autism Spectrum
Disorders. Major Professor: Charles D. Blaha, Ph.D.
While the etiology of autism is unknown, current research indicates that abnormalities of
the cerebellum, now believed to be involved in cognitive function, and the prefrontal
cortex (PFC) are associated with autism. The current paper proposes that impaired
cerebello-cortical circuitry could, at least in part, underlie autistic symptoms. The
evidence linking the cerebellum to autism and rodent models useful for elucidating
etiological factors in autism as well as their potential impact on cerebello-cortical
circuitry are reviewed. Recent research has demonstrated in wildtype mice that
stimulation of the dentate nucleus of the cerebellum (DN) evokes dopamine release in the
medial prefrontal cortex (mPFC). Therefore the current paper also investigated the
neuronal circuitry by which the cerebellum modulates mPFC dopamine release in mice.
Fixed potential amperometry was used to determine the contribution of two candidate
pathways by which the cerebellum may modulate mPFC dopamine release. In urethane
anesthetized wildtype mice, dopamine release evoked by DN stimulation was recorded in
mPFC following local anesthetic lidocaine or ionotropic glutamate receptor antagonist
kynurenate infusions into the mediodorsal or ventrolateral thalamic nucleus (ThN md;
ThN vl), or the ventral tegmental area (VTA). Also, to identify any compensatory
changes within the neural circuitry following a developmental cerebellar pathology,
mPFC dopamine release evoked by DN stimulation was recorded using the same
methodology in two mutant models: the FMR1 mutant mouse which has elongated
Purkinje cell spines and decreased volume of deep cerebellar nuclei, and Lurcher mutant
iv

mouse, which loses almost all Purkinje cells between the second and fourth weeks of life.
While the cerebello-thalamo-cortical and cerebello-ventral tegmento-cortical pathways
contributed equally to cerebellar modulation of PFC dopamine release in wildtype mice,
modulatory control shifted to the thalamus in both mutant mouse strains. Also, reductions
in dopamine release following lidocaine or kynurenate infusions were not significantly
different indicating that neuronal cells in the VTA and ThN were activated primarily if
not entirely by glutamatergic inputs. The current findings suggest that a loss or
impairment of cerebellar output has downstream effects on cerebellar-cortical circuitry
that could account for certain symptoms of autism.
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PREFACE
This dissertation has been formatted to allow for the separate publication of
Chapters 1, 3, and 4. As such, these chapters have been formatted according to the style
guidelines of the journals to which each has been or will be submitted. Chapter 1 titled
“Is Autism a Cerebellar Disease?” will be submitted to the journal Cerebellum. Chapter 3
titled “Connecting the Dots of the Cerebro-Cerebellar Role in Cognitive Function:
Neuronal Pathways for Cerebellar Modulation of Dopamine Release in the Prefrontal
Cortex” has been published in the journal Synapse. Chapter 4 titled “Examining
Adaptations of Cerebellar-Cortical Circuitry in Mouse Models with Developmental
Cerebellar Damage” will be submitted to The Journal of Neuroscience.
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CHAPTER 1
Is Autism a Cerebellar Disease?
Introduction
Autism spectrum disorders (ASD). Autism spectrum disorders are a group of
neurodevelopmental disorders that includes autism, Asperger’s syndrome, Rett
syndrome, childhood disintegrative disorders, and pervasive developmental disorders not
otherwise specified.1 Disorders within this spectrum are characterized by deficits in social
skills and communication, unusual and repetitive behavior, and a range of cognitive
function deficits that are diagnosed on average by 4.8 years of life, although symptoms
suggestive of autism have been observed as early as 6 months of age.1-6 Deficits in
cognitive function most commonly observed in autistic patients include impairments in
memory and attention as well as impairments in executive function including planning,
cognitive flexibility, rule acquisition, and abstract thinking.7
The etiology of autism. The etiology of autism is multifaceted. Genetic factors
are known to contribute to this disorder. According to studies investigating concordance
rates in twins, the heritability of autism is approximately 60-90%.8-9 Studies exploring the
contribution of genetics have revealed that multiple genes are likely contributors to this
disorder.10 Cytogenetic studies have found chromosomal abnormalities in regions such as
15q and 7q in autistic individuals.10-13 Variations within these chromosomal loci are
associated with an increased diagnosis of autism.11 Whole-genome scans implicate
chromosomes 1, 2, 4, 7, 10, 13, 15, 16, 17, 19, 22, and X.10 Cytogenetic studies and
whole-genome searches have yielded several candidate genes to be further researched.10
However, all the currently known genetic variations contributing to autism only account
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for approximately 7-8% of cases.14 It is therefore likely that genetic factors alone are not
sufficient to explain the etiology of autism.
Prenatal or perinatal environmental insults are also believed to contribute to
autism. The developing brain is particularly susceptible to environmental injury early in
development.15 Prenatal or neonatal exposure to certain chemicals, such as ethyl alcohol,
produces neuropsychological deficits similar to autism, and several environmental causes
have recently been shown specifically to result in both autistic symptoms and an
increased likelihood of a diagnosis of autism.14 These chemicals include thalidomide,
misoprostol, and valproic acid.16-18 However, similar to genetic explanations of autism,
exposure to known environmental agents accounts for a relatively small percentage of
cases.14 Therefore, it is possible that autism results from a specific and as yet unknown
combination of genetic predisposition and environmental insults with variation in these
causes determining the severity of the phenotype.
Despite the current gap in understanding the etiology of autism, abnormalities in
neuroanatomy, behavior, and the underlying genetics of patients diagnosed with autism
may provide some insight into the causes of autistic symptomology. The aim of the
current review is to suggest that accumulating preclinical and clinical research is
suggestive that, regardless of etiology, developmental pathology of the cerebellum likely
plays a very important role in autism and ASD. This hypothesis may provide a unifying
framework for understanding the diversity of autism research findings as well as
providing direction in the search for etiological factors in this disease.
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Evidence that Cerebellum is Involved in Autism and ASD
Although traditionally implicated in motor function, accumulating evidence
indicates that the cerebellum is also involved in cognitive function.19 The cerebellum is
structurally and functionally abnormal in patients diagnosed with autism or within the
ASD spectrum.20 Syndromes that share cognitive symptomology with autism also
frequently share genetic mutations associated with abnormal cerebellar development.
Structural cerebellar abnormalities are common in autism and ASD.
Cerebellar neuropathology commonly occurs in autistic individuals. Cerebellar
hypoplasia and reduced cerebellar Purkinje cell numbers are the most consistent
neuropathologies linked to autism.21-27 MRI studies report that autistic children have
smaller cerebellar vermal volume as compared to typically developing children.28
Postmortem studies report microanatomic abnormalities of the cerebellum in this
population including excess Bergmann glia, reductions in the size and number of cells in
the deep cerebellar nuclei, and an active neuroinflammatory process within cerebellar
white matter.29-31
Multiple disorders within the autism spectrum are also associated with cerebellar
abnormalities. For example, Asperger’s syndrome has been associated with lower total
cerebellar volume and lower gray matter volume in the right cerebellum.32-34 Diffusion
tensor magnetic resonance imaging has demonstrated that adults with Asperger’s
syndrome have reduced fractional anisotropy in the cortico-cortical parallel fibers and
Purkinje cell fibers of the cerebellum and superior cerebellar peduncle of the right
hemisphere, which indicates abnormal microstructure of cerebellar white matter.
According to postmortem studies, patients with Rett syndrome display reduced volume of
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the cerebellum, cerebellar atrophy, and reduced Purkinje cell number.35-36 Diffusion
tensor imaging of cerebellar pathways in children with ASD found increased diffusivity
of the superior cerebellar peduncles, suggesting abnormal connectivity between the
cerebellum and the rostral-going cerebellar projections.37
Abnormalities of cerebellar function in autism and ASD are associated with
cognitive deficits. Imaging studies indicate that in addition to neuropathological changes,
the cerebellum is functionally abnormal in autistic and ASD patients. Functional MRI
(fMRI) work has found that during a visually guided saccade task, autistic patients have
increased activation of cerebello-thalamic circuitry compared to controls.38 It has been
reported that activation of the ipsilateral anterior cerebellar hemisphere is increased in
magnitude and larger in spatial extent during simple motor tasks in autistic patients as
compared to control participants.39 In adults with Asperger’s syndrome, diffusion tensor
magnetic resonance imaging showed that the level of severity of social impairment was
significantly negatively correlated with the degree of anisotropy of the superior cerebellar
peduncle, the primary output track of the cerebellum. This suggests that as cerebellar
white matter decreases, symptom severity increases.40
ASD individuals and individuals with cerebellar abnormalities occurring during
development or following acute injury have similar cognitive impairments, suggesting
that the cerebellum is directly involved in autistic symptoms. Clinical studies have shown
that progressive cerebellar atrophy as well as acute cerebellar lesions caused by tumors or
infarction result in impairments to attention, planning, set-shifting, reversal learning,
verbal fluency, abstract reasoning, memory and associative learning.23,41-45 In individuals
with developmental reductions in cerebellar volume, cognitive functions such as

5

associative learning, verbal ability, planning, and working memory are impaired, and the
degree of volume reduction is correlated with the degree of cognitive impairment.46-48
Multiple genes necessary for normal cerebellar development are associated
with autism or autistic symptomology. Although single genes have diverse influences
on brain development, mutations of several genes that contribute to normal cerebellar
development are consistently associated with increased susceptibility to autism. These
genes include the retinoic acid-related orphan receptor-alpha (RORα),49 Engrailed 2
(EN2),50-52 Ca2+-dependent activator protein for secretion 2 (CAPS2),53 and
mesenchymal-epithelial transition (MET) receptor tyrosine kinase.11 RORα is a gene
required for differentiation of cerebellar Purkinje cells.54 The EN2 gene has been
associated with normal cerebellar development,55 and mutations or deletions of EN2
result in reduced volume in the cerebellum and foliation abnormalities.56 CAPS2
contributes to normal cerebellar development by enhancing release of brain derived
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3).53,57 The MET receptor gene has
been found to contribute to pre- and post-natal cerebellar proliferation as well as
migration of cerebrocortical cells.58-60
Genetic mutations associated with increased risk for syndromes associated with
autistic symptomology are also associated with abnormal cerebellar development.
Patients with fragile X syndrome, which results from a mutation of the fragile X mental
retardation 1 (FMR1) gene, exhibit cognitive symptoms similar to autism such as
hypersensitivity to auditory, tactile, gustatory and olfactory stimuli, deficits in attention,
mental retardation, and perseveration.61-62 Cerebellar abnormalities such as ectopic
Purkinje cells, focal cerebellar Purkinje cell loss, and Bergmann gliosis are associated
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with fragile X syndrome.63,64 Mutations of the methyl CpG-binding protein 2 (MECP2)
gene are known to produce Rett syndrome, a disorder within the autism spectrum
characterized by language impairments, motor impairments, and stereotypical behavior.65
Patients with Rett syndrome frequently have cerebellar atrophy that increases with age.35
Autism Disconnection Hypothesis
Together, the recent findings implicating the cerebellum in autism suggest that by
genetic and/or environmental causes, neuropathological changes in the cerebellum occur
in individuals with ASD. These changes may then result in a loss or dysregulation of
cerebellar output leading to a cascade of events which either directly or indirectly results
in the behavioral and cognitive symptoms associated with the diagnosis of autism or
ASD. Thus, the autism disconnection hypothesis presented here posits that a
disconnection in the autistic brain occurs as a result of developmental cerebellar
neuropathology and particularly the loss of Purkinje cells in the cerebellar cortex as these
cells constitute the outflow of cerebellar cortex.26-27,66
The disconnection hypothesis asserts that the etiology of a given disorder can be
accounted for by a loss of connectivity between two or more brain areas.67 While this
theory was originally used to explain literal severances of circuitry, this hypothesis has
more recently been expanded to include developmental neuropathology or disturbance or
dysregulation of neural circuitry resulting in impaired functional connectivity.68-69 A
disconnection occurring due to a change in cerebellar output in autistic patients could
result not only in impaired communication between the cerebellum and its efferent
targets, but also in compensations or adaptations of affiliated neuronal circuitry.
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It is possible that a disconnection of cerebello-cortical projections could account
for many of the cognitive symptoms of autism. Middleton and Strick70 used retrograde
transportation of herpes simplex virus to trace multiple closed-loop, basal ganglia- and
cerebellar-cortical circuits. Notably, this study reported that the cerebellum projects, via
the thalamus, to areas 46 and 9l of the prefrontal cortex (PFC) which is known to be
involved in cognitive functions such as memory, planning, and decision making.70-71
More recent research also provides a second cerebellum-PFC circuit that could influence
cognitive functions commonly attributed to the frontal cortex. The cerebellum projects
indirectly to the ventral tegmental area (VTA) which contains dopamine cell bodies
comprising the mesocortical dopaminergic system that terminates in the PFC.72 Abundant
evidence links PFC dopaminergic function to a number of important cognitive abilities
including working memory, attentional selection, and cognitive flexibility.73 Therefore, a
loss of cerebellar output could result in significant downstream effects on either of these
cerebellar-PFC circuits that, in turn, could result in deficits in higher cognitive functions
that commonly occur in autism and ASD.
The proposed neuronal circuitry, based on these findings, by which the
cerebellum modulates PFC dopamine release is illustrated in Figure 1. Both of these
neuronal circuits originate in cerebellar cortex Purkinje neurons that project to the deep
cerebellar nuclei (DN, in particular). The cerebellar-ventral tegmental-cortical circuit
involves indirect activation of mesocortical dopaminergic neurons via contralateral
projections of the DN to reticulo-tegmental nuclei (RTN) that, in turn, project to
pedunculopontine nuclei (PPT) and then project to, and stimulate directly, VTA
dopaminergic cell bodies projecting to the medial PFC (mPFC) .74-80 The cerebello-
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thalamocortical circuit involves activation of the contralateral projections of the DN to
thalamic mediodorsal/ventrolateral nuclei (ThN md/vl) that send afferents to the mPFC to
modulate mesocortical dopaminergic terminal release in the mPFC via appositional
excitatory glutamatergic synapses (see Figure 1).76,81-83 Considered together, this research
suggests that changes in either or both of these circuits could result in aberrant
dopaminergic activity in the PFC.
If developmental cerebellar damage affects PFC processing, it should be expected
that abnormalities in the target structure (i.e., PFC), as well as at the level of the neural
junctions within these circuits (i.e., thalamus and VTA), should occur in autistic
9ransducer9. As previously discussed, several cerebellar abnormalities are affiliated with
autism, but recent research also suggests that the PFC and thalamus are abnormal in these
individuals.84-85 While abnormalities of the VTA in autistic individuals have been
infrequently investigated, some studies suggest abnormal dopamine function in the PFC
occurs in these individuals86, thus implicating a role of this pathway in cognitive
symptoms of autism and ASD.
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Figure 1. Neural circuitry involved in cerebellar modulation of prefrontal cortex
dopamine and proposed to be affected by a developmental disconnection in autism. With
the exception of inhibitory cerebellar to dentate nucleus projections, red arrows indicate
glutamatergic pathways. The green arrow indicates the mesocortical dopaminergic
pathway. Dotted black arrow indicates feedback loop. See text for additional details and
references.20, 76

Abnormalities of the PFC are associated with autism. A cerebello-PFC
disconnection in autism would imply that the PFC is structurally and/or functionally
abnormal in autistic patients. Studies investigating structural abnormalities of the PFC
indicate that the frontal cortex is larger in individuals with autism, and increased volume
of frontal cortex has been shown to be positively correlated with autistic symptoms.84,87
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Most significantly, the degree of enlargement of the frontal cortex is also positively
correlated with the degree of hypoplasia in the cerebellum.88 In addition, imaging studies
indicate abnormal PFC function in patients with autism. Positron emission tomography
(PET) studies demonstrate abnormal mPFC activation during theory of mind tasks and
facial expression processing in autistic patients.89-92 Recent fMRI studies also show lower
activity levels within the mPFC in individuals with autism during a spatial working
memory task.93 Furthermore, multi-voxel pattern analyses following fMRI during
attentional tasks have shown that the spatial distribution of activation of the mPFC differs
between those with and without autism suggesting abnormal functional organization of
the mPFC in autistic patients.90
The involvement of either the cerebello-ventral tegmental-cortical pathway or the
cerebello-thalamocortical pathway in autism would implicate dopaminergic dysfunction,
as the cerebellum modulates PFC dopamine release by both of these neuronal circuits.
Although to-date this possibility has been sparsely investigated in human patients, there
is a small amount of concordant evidence. For example, systemic administration of
dopamine antagonists such as haloperidol or risperidone has been shown to reduce
aggressive behaviors, social impairments, and stereotypies in autistic patients.94-96 In
contrast, administration of bromocriptine, a dopamine agonist, has also been shown to
have therapeutic effects such as a reduction in hyperactivity and attention deficits for
autistic patients.97 Recent biochemical analysis of cerebrospinal fluid (CSF) levels of
dopamine metabolites such as homovanillic acid (HVA) have produced conflicting
results, with some studies reporting elevated levels in autistic patients and others
reporting no differences between patients and controls.98 These disparate biochemical
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findings may not be surprising given that CSF levels of neurotransmitter metabolites
reflect whole brain neurotransmission activity. A single PET study has demonstrated that
children with autism have reduced dopaminergic activity in the mPFC.86 While current
evidence of dopamine dysfunction in autistic patients is inconsistent, relatively few
studies have investigated dopamine localized to specific brain areas. Therefore, it is
possible that dopaminergic activity within certain brain areas, such as the PFC, is
abnormal in autistic individuals.
Abnormalities of the thalamus are associated with autism. If the cerebellothalamocortical circuit is involved in autism, abnormalities of the thalamus should also be
expected in autistic patients. Recent MRI studies indirectly corroborate this notion by
concluding that while total brain volume is positively correlated with the volume of the
thalamus in control brains, a lack of correlation exists between total brain volume and
volume of the thalamus in autistic brains.85,99-100 The size of the thalamus in autistic
individuals is reduced when compared to controls, and the size of the left thalamus in
children with ASD is inversely correlated with stereotypical and repetitive behaviors.100101

Mizuno and colleagues102 also report that the temporal correlation between

neurophysiological events in the thalamus and the cortex in autistic individuals exceeds
that of controls, as measured by functional connectivity MRI (fcMRI). Additionally,
during a visually guided saccade task, autistic individuals have been shown to have
greater activation of the medial thalamus as compared to controls.38 The thalamus has
also been implicated in cognition in non-autistic individuals as lesions to the thalamus,
particularly the mediodorsal nuclei, result in autism-like cognitive deficits such as poor
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working memory, perseveration, failure to inhibit inappropriate behaviors, and language
deficits during recall and recognition tasks.103-104
Rodent Models with Cerebellar Abnormalities
The abovementioned research clearly implicates the cerebellum in autism.24
Similarly, the PFC and thalamus have also been implicated in this disorder, which could
possibly be explained by downstream effects of cerebellar pathology on cerebello-cortical
circuitry. Abnormalities in structure and function of all these areas have been associated
with the appearance or severity of autism symptoms.84,100 However, research
investigating brain circuitry in autistic individuals is necessarily limited by a number of
methodological constraints. The use of animal models allows for manipulation of genetic
and environmental influences and, because of this, is an effective means of elucidating
both distal and proximal etiological factors and their potential impact on cerebellocortical circuitry. Some existing rodent models of autism, as well as some models not
previously applied to the study of this disorder, display cerebellar, behavioral, and motor
abnormalities that parallel those commonly seen in autistic patients. Genetic, viral
infection, toxic exposure, and developmental neuropathology models exist that display
the signature psychomotor impairments and cerebellar pathology of autism, and are
therefore useful for investigating the behavioral impact of changes in cerebello-cortical
circuitry. The novel findings produced from research utilizing rodent models could
therefore confirm and extend our understanding of the neurochemical and behavioral
impact of changes in cerebellar-cortical circuitry.
Genetic models. As previously discussed, autism is known to be a product of
multiple genetic mutations and is highly heritable. Genetic mutations associated with
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autism, ASD, and similar cognitive disorders have been replicated in rodents. As shown
in Table 1, some of these rodent models display both autism-like behavior and cerebellar
pathology including the fragile X mental retardation 1 (FMR1) knockout mouse, the
engrailed homeobox 2 (EN2) knockout mouse, and the staggerer mouse.105-111 Similarly,
the Shank3 gene has been associated with behavioral and cerebellar abnormalities,
making Shank3 mutant mice potential candidates for investigations of impaired
cerebello-cortical circuitry.112-113 Also included in this category is the Lurcher (Lc/+)
mouse, a mutant with a gain of function in the gene that encodes the Grid2 locus
(glutamate receptor, ionotropic, delta2).114 Although the Grid2 locus has not been
associated with autism or ASD, there is substantial overlap between the morphological
and behavioral phenotypes between these mice and patients with these disorders.
FMR1 knockout mice. The FMR1 gene codes for the production of the fragile X
mental retardation protein known to be involved in cognitive development, and mutations
of this gene result in fragile X syndrome.115-116 As previously discussed, patients with
fragile X syndrome exhibit autism-like cognitive symptoms and have an increased
probability of autism diagnosis.62,111 Because of this, FMR1 knockout (KO) mice have
been used to model autism. These mice display several behavioral deficits similar to
those seen in autism such as hyperactivity, perseverative behavior, reduced spatial
learning abilities, memory deficits, and reduced fear conditioning.117-119 FMR1 KO mice
have cerebellar abnormalities such as elongated spines on cerebellar Purkinje cells and
decreased volume of cerebellar nuclei.106,120 Also, eye-blink conditioning, known to be
dependent on synaptic plasticity of cerebellar neurons,121 is attenuated in FMR1 KO mice
suggesting that these cerebellar abnormalities are functionally relevant.120 Abnormalities
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also exist in the PFC of FMR1 KO mice. Layer 5 pyramidal neurons display
hyperconnectivity in the mPFC and synapses between these neurons are not able to
recover from long term depression as rapidly as the same neurons in control mice.122
EN2 knockout mice. EN2 gene has been associated with autism.50,110 EN2 is a
transcription factor that regulates gene expression necessary for normal cerebellar
development. Thus, EN2 KO mice also have cerebellar abnormalities that resemble those
observed in autism such as hypoplasia, a reduction in the number of Purkinje cells by
approximately 40%, and foliation defects.108,123 EN2 has also been identified as important
for the development and survival of midbrain dopaminergic neurons such as those located
in the VTA.124-125 EN2 KO mice display social impairments which parallel symptoms of
autism including decreased play, social behavior, and aggressive behavior as compared to
controls.126
Staggerer mutant mice. The staggerer mouse has a mutation of the retinoic acid
receptor-related orphan receptor alpha (RORα) gene which has been associated with
autism.49,127 This gene is responsible for Purkinje cell survival and differentiation.128 The
staggerer mouse has cerebellar hypoplasia resulting from a perinatal loss of
approximately 80% of Purkinje cells with the remaining Purkinje cells displaying defects
such as reduced size and ectopic location.105,129-130 Other cerebellar abnormalities such as
a near 100% reduction in the number of granule cells and reduced volume of the
cerebellar nuclei are also noted in these animals.131-132 These mice are ataxic, which
limits behavioral research, but have been found to display behavioral deficits including
impaired spatial learning and reversal learning, memory deficits, perseverative behavior,
and abnormal responses to novel environments.107,109,133-134
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Shank3 mutant mice. In humans, the Shank3 gene is found at chromosome 22q13
and codes for a structural protein necessary for the maintenance and plasticity of
postsynaptic densities located in excitatory synapses. 135-136 An abnormal Shank3
mutation accounts for approximately 2% of autism cases and has been associated with the
occurrence of cognitive deficits and disorders with similar cognitive phenotypes such as
chromosome 22q13 deletion syndrome.112,137-140 Autistic patients with Shank3 deletions
are also noted to have severe core symptoms and mental retardation.140 Multiple models
exist with Shank3 mutations, and several display behaviors analogous to the core
symptoms of autism.112,113,139,141 For example, the isoform-specific Shank3 (e4-9)
homozygous mutant exhibits abnormal social behaviors, repetitive behaviors, and
learning and memory deficits.113 Although research has not yet directly addressed the
effect of Shank3 mutations on cerebellar anatomy and function, recent research suggests
that mutations of Shank3 may be related to cerebellar abnormalities in both humans and
rodents. Shank3 has been shown to be tissue-specific with high expression in the
cerebellar granule cells.112,142 Shank3 has also been suggested to play an important role in
the recruitment of axon terminals to cerebellar granule cell dendrites.143 In addition,
mutations of Shank3 are associated with abnormalities or reduced synaptic expression of
glutamate receptors.141,144
Lurcher mutant mice. Lurcher mutant mice have an autosomal dominant
mutation that results in nearly a complete loss of Purkinje cells between the 2nd and 4th
weeks of life.114,145 Since these mice are ataxic and display characteristic lurching
movements, chimeric mice, which have a variable loss of Purkinje cells dependent upon
the incorporation of the wildtype lineage, are used to examine the behavioral impact of
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Purkinje cell loss.146 Lurcher mice and chimeras display impaired executive function as
measured by a serial reversal learning task, and learning errors were negatively correlated
with the number of Purkinje cells in subsequent cell counts.147 Belzung and colleagues148
found that Lurcher mutant mice showed memory deficits in a radial arm maze. Martin
and colleagues149 found a negative correlation between repetitive behaviors and
cerebellar Purkinje cell number in chimeric mice. Thus, these mice exhibit executive
dysfunction and repetitive behaviors directly related to cerebellar Purkinje cell numbers
and approximate the symptoms commonly observed in autism and ASD.
Recent research in Lurcher mice has also explored the cerebello-thalamocortical
and cerebello-ventral tegmental-cortical circuits. Mittleman and colleagues76 used fixed
potential amperometry (FPA) to detect dopamine release in the PFC following electrical
stimulation of the cerebellar Purkinje cell layer or dentate nucleus (DN) of the cerebellum
in mice. In Lurcher mice with significant developmental cerebellar Purkinje cell loss,
dopamine release following stimulation at either site was markedly attenuated in
comparison to littermate mice with normal Purkinje cell numbers.
Rogers and colleagues78 further examined these two neuronal circuits by using
FPA to detect DN stimulation-evoked dopamine release in the PFC of mice before and
after infusions of lidocaine, a local anesthetic, or kynurenate, a broad spectrum glutamate
ionotropic receptor antagonist, into the VTA, mediodorsal thalamus, or ventrolateral
thalamus. Both lidocaine and kynurenate infusions into the VTA resulted in a comparable
decrease in dentate stimulation-evoked PFC dopamine release (~50%). In a similar
fashion, lidocaine or kynurenate infusions into the thalamus resulted in approximately
50% decrease in dentate stimulation-evoked dopamine release in the PFC suggesting that
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these pathways equally contribute to PFC dopamine modulation and that they are
primarily, if not entirely, glutamatergic. Although the Lurcher and chimera models have
no known genetic overlap with autism, these findings are important because they
demonstrate that developmental cerebellar neuropathology in the form of Purkinje cell
loss is associated with autistic-like symptomatology as well as a dysregulation of
dopamine release in the PFC.
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Table 1. Summary of genetic rodent models with cerebellar and behavioral abnormalities that parallel those observed in
autism. See text for details and references.
Rodent Model

Behavioral Abnormalities

Cerebellar Abnormalities

Prefrontal Cortex Abnormalities

FMR1 KO Mice



Hyperactivity







Reduced spatial learning





Memory deficits



Reduced fear conditioning



Decreased play



Cerebellar hypoplasia



Decreased social behaviors



Decreased Purkinje cell 

Elongated spines on Purkinje 
cells

EN2 KO Mice


Staggerer Mutant Mice



Foliation defects

Impaired spatial and 



Cerebellar hypoplasia

Decreased Purkinje cell 
number


Abnormal responses to
novel environments

cells do not recover from LTD as quickly

number


Memory Defictis


Synapses between layer 5 pyramidal 
as controls

Reduced aggressive

Perseverative behavior

cells


cerebellar nuclei

behavior
 reversal learning


Decreased volume of deep 

Hyperconnectivity of layer 5 pyramidal 

Ectopic and atrophic Purkinje 
cells



Decreased number of granule
cells






Shank3 Mutant Mice

Lurcher Mutant Mice



Social abnormalities



Repetitive behavior



Learning and memory 



deficits



Impaired behavioral 



flexibility


Reduced volume in deep
cerebellar nuclei


Decreased Purkinje cell 
number

Repetitive behavior
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Decreased PFC dopamine release 
following DN stimulation

Viral infection models. Children with autism display a variety of inflammatorylike abnormalities in the brain and periphery suggesting autoimmune system
activation.150 Viral infections and maternal immune activation have therefore been
suggested to play a role in the etiology of autism.151-153 Atladóttir and colleagues154
determined that maternal viral infection occurring in the first trimester is associated with
the diagnosis of autism. Viral infections of developing nervous systems can alter normal
development making the risk of neuropathology following prenatal or neonatal exposure
particularly high for areas including the cerebellum and neocortex that continue to
develop after birth.155-156 As shown in Table 2, cerebellar and frontal cortex abnormalities
following viral infection have been demonstrated in two rodent models, the neonatal
Borna disease virus infection rat model and the maternal influenza infection mouse
model. These two animal models also display autism-like behavioral deficits making
them useful for evaluating behavioral changes following developmental cerebellar
pathology.
Neonatal Borna disease virus infection rats. Borna disease virus (BDV) is a
nonsegmented, negative, single-strand virus that replicates in neuronal nuclei of many
species and produces a range of neurological symptoms such as motor, sensory, and
emotional impairments.157-159 Although BDV is not considered a potential cause of
autism, BDV rodent models have neuroanatomical and behavioral abnormalities
representative of the disorder. Rats neonatally exposed to BDV display several
behavioral impairments including hyperactivity, impaired spatial learning, memory
deficits, decreased open-field exploration, stereotypic behavior, and deficits in social
behavior.160-162 Neonatal BDV infection in rats produces cerebellar hypoplasia and has a
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relatively high specificity for Purkinje cells resulting in up to 75% loss of cerebellar
Purkinje cells.157,160-161,163-165 Solbrig and colleagues166 employed high performance liquid
chromatography (HPLC) to investigate the PFC of infected rats and found high levels of
viral nucleic acid and elevated levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the PFC suggesting a role for PFC dopamine hyperactivity
in the behavioral changes observed in this model.
Maternal influenza infection mice. In a sample of mothers hospitalized during
pregnancy, 50% of those whose offspring was diagnosed with autism were hospitalized
due to influenza. Also, according to this study, the frequency of autism diagnosis among
children of mothers exposed to influenza during the first trimester was approximately 6
times higher than in the general population.154 Similarly, rodents prenatally or neonatally
exposed to influenza virus display a range of behavioral deficits including social
impairments and cognitive deficits, such as impaired working memory and impaired
emotional behavior.167-169 Atrophy of the cerebellum and gene expression changes in the
PFC and cerebellum have also been observed in mice prenatally exposed to influenza
virus.170-171 Most significantly, prenatal exposure to influenza in mice results in
approximately 33% decrease in Purkinje cell numbers, heterotopic Purkinje cells, and
delayed migration of granule cells in the cerebellum.172 Also, Fatemi and colleagues173
observed an increase in GAD 67-kDa protein, a rate limiting enzyme that modulates
conversion of GABA from L-glutamate, in mice exposed to influenza and suggested that
this was evidence of aberrant glutamatergic activity.
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Table 2. Summary of viral infection rodent models with cerebellar and behavioral abnormalities that parallel those observed in
autism. See text for details and references.
Rodent Model

Behavioral Abnormalities

Cerebellar Abnormalities

Prefrontal Cortex Abnormalities

Neonatal Borna Disease Virus



Hyperactivity



Cerebellar hypoplasia



High levels of viral nucleic acid in PFC

Infection Rats



Stereotypic behavior



Decreased Purkinje cell 



Elevated levels of DOPAC



Deficits in social behavior



Gene expression changes in PFC

Maternal Influenza Infection Mice



number

Reduced exploratory 



Atrophy of cerebellum

behavior



Gene expression changes in 



Social impairments

cerebellum



Working memory deficit





Impaired emotional 
behavior

Decreased Purkinje cell 
number



Heterotopic Purkinje cells



Delayed migration of granule 
cells





Toxic Exposure Model. Environmental factors such as exposure to toxic chemicals during pregnancy are also thought
to contribute to autism. Thus, some rodent models utilize prenatal or neonatal exposure to teratogens known to be associated
with autism. One such model is the prenatal valproic acid exposure rat model display signature behavioral and cerebellar
abnormalities that parallel those observed in autism.174
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Prenatal valproic acid exposure rats. Valproic acid (VPA) is an antiepileptic
drug found to be positively correlated with the occurrence of autism in the offspring of
mothers exposed to the drug during pregnancy.175 In humans, the behavior resulting from
prenatal exposure includes delayed speech and motor development, hyperactivity, poor
social and communication skills, and deficits in cognitive functions such as attention.17
Likewise, mice and rats prenatally exposed to VPA exhibit abnormal behaviors including
deficits in olfactory discrimination, decreased prepulse inhibition, hyperactivity,
increased stereotypy, decreased social play, and decreased exploratory behavior, as
compared to controls.176-177 Rats prenatally exposed to VPA also exhibit cerebellar
abnormalities. Yochum and colleagues178 found that prenatal exposure to VPA in rats
induced an increase in apoptotic cells in the cerebellum, and Ingram and colleagues179
found that rats prenatally exposed to a single VPA intra-peritoneal injection had
approximately 30% fewer Purkinje cells and significantly differed from control animals.
Consistent with the disconnection hypothesis, VPA seems to have an effect on dopamine
tissue levels in adult rodents following acute or chronic exposure.180 Adult rats that
received chronic i.p. injections of VPA had increased dopamine tissue levels in multiple
brain areas, including frontal cortex, as measured by HPLC.181 Also, an in vivo
microdialysis study found that an acute subcutaneous injection of VPA produced
increased extracellular dopamine levels in the mPFC of rats.182
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Table 3. Summary of toxic exposure rodent model with cerebellar and behavioral abnormalities that parallel those observed in
autism. See text for details and references.
Rodent Model

Behavioral Abnormalities

Cerebellar Abnormalities

Prefrontal Cortex Abnormalities

Prenatal Valproic Acid Exposure



Deficits in olfactory 





discrimination



Rats


Decreased prepulse 

Apoptotic cells in cerebellum

Aberrant dopamine activity in PFC

Decreased Purkinje cell 
number

inhibition


Hyperactivity



Increased stereotypy



Decreased social play



Decreased exploratory 
behavior




Summary and Conclusions
Rodent models of autism both confirm often reported clinical findings and also extend these findings by providing
candidate pathways deserving of further research. It is apparent from clinical research that developmental damage to the
cerebellum is a common occurrence in autism and ASD. Pre-clinical research confirms clinical observations that there are
multiple routes to developmental cerebellar damage including genetic mutations, viral exposure or exposure to environmental
toxins, although both types of research are potentially limited by questions about the selectivity of cerebellar abnormalities as
opposed to the rest of the brain. It is however intriguing to note that developmental damage to the cerebellum is frequently
associated with a diagnosis of autism or ASD in humans, and cerebellar neuropathology is associated with many autism-like
cognitive deficits in rodents.
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Equally important, pre-clinical research has demonstrated that two glutamatergic
pathways from the cerebellum to the PFC can modulate PFC dopamine release. This is
significant because impairments in attention, memory, and a marked tendency to
perseverate in the face of changing contingencies (i.e. executive function) that are well
documented in patients with autism or ASD and are well known to be dependent on ongoing dopaminergic activity in the PFC.183 Research in lurcher mice has shown that the
ability of the cerebellum to modulate PFC dopamine release is significantly altered by
developmental loss of cerebellar Purkinje cells, and that cerebellar Purkinje cell number
is significantly correlated with autism like deficits in executive function, working
memory and repetitive behavior. Thus it is possible that cerebellar neuropathology that
results in changes in cerebellar output and subsequent effects on downstream circuitry
might underlie some of the cognitive symptoms of autism.
While it seems clear that cerebellar modulation of PFC dopamine release is
dependent on glutamatergic pathways, there remains a significant gap in our knowledge
of the role of dopaminergic and glutamatergic systems in autism. Several molecular
biological techniques are available for investigating this in rodents, including the use of
viral vectors to selectively 25ransducer, or introduce new genetic material into
glutamatergic neurons. This might provide a way to understand the behavioral
consequences and ameliorate behavioral impairments of altered glutamatergic
transmission within this circuitry. Future research should also aim to determine when
during the developmental time course the cerebellar lesions occur and the anatomical
specificity of the cerebellar deficits observed in the reviewed rodent models.
Understanding the developmental timing and the anatomical specificity of cerebellar
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pathology is important for understanding the causal mechanisms underlying this
consistent feature of autism. Ultimately, a better understanding of the direct effects of
cerebellar pathology in autism could lead to better diagnostic measures, earlier diagnosis,
and novel pharmacological targets for the treatment of autism and ASD.
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CHAPTER 2
Fixed Potential Amperometry Methodology
The experimental studies in Chapters 3 and 4 utilize in vivo fixed potential
amperometry (FPA), an electrochemical technique used to detect the release of oxidizable
neurotransmitters (Blaha & Phillips, 1996). FPA uses a three-electrode configuration that
incorporates an auxiliary electrode, reference electrode, and recording electrode (see Fig.
1) (Blaha & Phillips, 1996). For the experiments described in Chapters 3 and 4, FPA was
employed using a silver/silver chloride reference and stainless steel auxiliary electrode
combination in contact with brain tissue paired with a carbon fiber recording electrode
implanted in the medial prefrontal cortex (mPFC). An electrometer and analog to digital
chart recorder (EA162 Picostat and ED401 e-corder 401, eDAQ Inc., Colorado Springs,
CO, USA) creates a circuit between the three electrodes, allowing the application of a
fixed continuous potential of +0.8 V to the recording electrode via the auxiliary electrode,
while maintaining a potential difference between the recording and reference electrode
(Blaha & Phillips, 1992). Continuously applying a potential to the recording electrode
allows dopamine to be continuously oxidized at the electrode surface. Thus, FPA
provides high temporal resolution (10,000 samples/sec or higher dependent on the analog
to digitial converter of the recording device) for the recording of phasic dopamine release
in vivo. Although electrochemical techniques generally have lower chemical selectivity,
pharmacological studies have validated the selectivity of FPA as a measurement of
electrically-stimulated dopamine efflux in vivo (Dugast et al., 1994; Forster & Blaha,
2003; Mittleman et al., 2008). Specifically, this has been demonstrated by significant
increases in Purkinje cell layer stimulation-evoked oxidation current in the mPFC of mice
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in response to systemic administration of the dopamine reuptake inhibitor nomifensine,
but not following a combined serotonin and norepinephrine reuptake blockade with
fluoxetine and desipramine (Mittleman et al., 2008). This in vivo technique has been
utilized commonly to evaluate the kinetics of stimulation-evoked dopamine release and
reuptake and drug-induced changes in the magnitude and temporal pattern of dopamine
neurotransmission (Benoit-Marand et al., 2000; Dugast et al., 1994; Forster & Blaha,
2003; Lee et al., 2006; Lester et al., 2008; Suaud-Chagny et al., 1995).

51

Figure 1. Simplified diagram of a three-electrode system used in amperometric
electrochemical recordings. The electrometer applies an electrical potential to the
auxiliary (AUX) electrode that is suitable to oxidize dopamine (DA) at the surface of the
recording electrode (RE), which is held constant relative to the reference electrode (REF).
Oxidized dopamine molecules transfer electrons to the RE which are measure as current
flow via the electrometer (EA162 Picostat) and passed as an analog signal to the analog
to digital chart recorder and (ED401 e-corder 401) where it is converted to a digital signal
for display via Chart software on a computer monitor in near real time. Adapted from
Blaha & Phillips (1996).
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Electrochemical Recording Electrodes Used in FPA
The pyrolytic-based carbon of the carbon fiber microelectrodes utilized in the
experimental studies of Chapters 3 and 4 provides an electrochemically inert surface
covered with oxygen-containing functional groups that facilitate electron transfer from
compounds undergoing oxidation or reduction at the electrode surface (Kawagoe et al.,
1993). Carbon fiber microelectrodes to record stimulation-evoked dopamine release in
vivo were fashioned by threading a single carbon fiber (10 µm o.d.) through a borosilicate
glass capillary tube. The tube was then heat-pulled to form a tip through which the carbon
fiber protruded. Carbon paste was packed into the bore of the electrode and a wire
inserted to make contact with the fiber. The wire was secured in place with carbon paste
made by mixing super glue with carbon powder (see Fig. 2). The protruding carbon fibers
were cut under a stereomicroscope so that the active recording electrode surface was
approximately 250 µm long. A new carbon microelectrode was used in each animal. As a
consequence of its small size, the carbon fiber recording electrode results in minimal
tissue damage at the site of insertion allowing for high degree of local specificity and
faster sampling of the dopamine oxidation current as there is less depletion of the
neurochemical at the electrode surface (Forster & Blaha, 2003; Kawagoe et al., 1993;
Stamford, 1989).
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Figure 2. Illustration of the carbon fiber recording electrode fabricated for use in fixed
potential amperometry to monitor the oxidation of dopamine in vivo.

Stereotaxic Surgery and Recording Set-up for FPA
Mice were anesthetized with urethane (1.5mg/kg) and mounted in a stereotaxic
frame (David Kopf Instruments, Tujunga, CA, USA) within a mouse head-holder adaptor
(Stoelting, Wood Dale, IL, USA). Stereotaxic coordinates for each target site were
determined from the mouse atlas of Paxinos and Franklin (2001). As shown in Fig. 3, in
each mouse a concentric bipolar stimulating electrode (SNE-100; Rhodes Medical Co.,
CA, USA), a 31 g stainless-steel guide infusion cannula, and a carbon fiber recording
microelectrode is implanted into the target brain areas. A silver/silver chloride reference
and stainless-steel auxiliary electrode combination was placed on cortical tissue
contralateral to the dopamine recording electrode.
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Figure 3. Schematic diagram of the mouse brain illustrating a typical setup for in vivo
fixed potential amperometric recording of stimulation-evoked medial prefrontal cortex
(mPFC) dopamine release. In the experiments in Chapters 3 and 4, a carbon-fiber
recording electrode was positioned in the striatum. A stimulating electrode was
positioned in cerebellar dentate nucleus (DN). A silver/silver chloride reference and
stainless-steel auxiliary electrode combination was placed in contact with contralateral
cortical tissue, and a drug infusion cannula is implanted into the ventral tegmental area
(VTA), the mediodorsal thalamic nuclei (md ThN), or the ventrolateral thalamic nuclei
(vl ThN).

Amperometric recordings are made within a Faraday cage to increase the signal to
noise ratio (Forster & Blaha, 2003). The stimulations consisted of 100, 0.5 msec pulses at
50 Hz delievered every 30 sec over a 30 minute testing period via an optical isolator and
programmable pulse generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel). With the
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addition of microinfusions of drugs, FPA lends itself to the investigation of the role of
receptor subtypes in stimulation-evoked phasic dopamine efflux. Intracerebral infusions
of the local anesthetic lidocaine is an effective means of temporarily blocking all axonal
transmission to or from specific areas and pathways with recovery approximately 10 min
post-infusion (Blaha et al., 1997; Foresco et al., 1998). By temporarily blocking
transmission through one of these sites, it is possible to determine the functional
neuroconnectivity of cerebello-cortical circuitry that mediates cerebellar dentate nucleus
(DN) stimulation-evoked dopamine release in the mPFC. Furthermore, infusions of
specific receptor antagonists help determine the neurochemical nature of the neuronal
pathways involved in mediating stimulation-evoked striatal dopamine release. To confirm
that the observed drug effects are not attributable to non-specific effects of the
microinfusion procedure, microinfusions of sterile phosphate-buffered saline (PBS,
pH~7.4) served as a control.

Post-Experimental Procedures
Upon completion of each FPA session, the stimulation, recording, and infusion
sites were marked, either by lesioning or stain infusion. Mice are uthenized with an
intracardial injection of urethane and brains are removed and stored until sectioning.
Coronal sections are sliced in a cryostat and observed under a light microscope to
confirm that the placements of stimulating electrodes, recording electrodes, and drug
infusion cannulae are within the anatomical boundaries of the target site.
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Chapter 3
Connecting the Dots of the Cerebro-Cerebellar Role in Cognitive Function:
Neuronal Pathways for Cerebellar Modulation of Dopamine Release in the
Prefrontal Cortex

INTRODUCTION
The cerebellum is heavily implicated in autism, schizophrenia and other cognitive
and affective disorders (Palmen et al., 2004; Andreasen and Pierson, 2008; Schmahmann
et al., 1998; Stoodley, 2011). For example, brains of autistic individuals have been
shown to have histopathological abnormalities in this structure. Cerebellar hypoplasia
and reduced Purkinje cell numbers are the most reproducible neural pathologies linked
with autism (Palmen et al., 2004; Vargas et al., 2005; Whitney et al., 2008). How
abnormalities in a structure traditionally linked to motor function, posture, and balance
contribute to the cognitive deficits is unknown (Morton and Bastian, 2004).
Clues to how cerebellar abnormalities may contribute to the cognitive and
affective deficits come from multiple sources. Recent imaging studies in primates and
humans revealed strong functional connectivity between the cerebellum and prefrontal
cortical areas (Krienen and Buckner, 2009). In mice and rats, recent research indicates
that both Purkinje cell degeneration and lesions to cerebellar dentate nucleus result in
visuospatial and sensorimotor learning deficits (Goodlett et al., 1992; Joyal et al., 2001;
Noblett and Swain, 2003). Clinical studies have shown that cerebellar lesions and
cerebellar atrophy result in cognitive and emotional impairments similar to those
associated with autism (Botez-Marquard and Botez, 1993; Bracke-Tolkmitt et al., 1989;
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Schmahmann and Sherman, 1998). Developmental abnormalities or acute lesions of the
cerebellum result in cognitive function deficits in associative learning, verbal ability,
planning, and working memory which suggests that the cerebellum is directly involved in
these functions. (Bracke-Tolkmitt et al., 1989; Kumar, et al., 2010; Rapoport, et al., 2000;
Schmahmann, 2001; Schmahmann, 1991; Schmahmann and Sherman, 1998).
Structural abnormalities of the medial prefrontal cortex (mPFC) have been shown
to exist in children with autism. The cortex of the frontal lobe is larger in individuals with
autism, and increased volume of frontal lobe cortex has been demonstrated to be
positively correlated with autistic symptoms and the degree of abnormality of the frontal
cortex is correlated with the degree of abnormality in the cerebellum (Carper and
Courchesne, 2000; Kumar et al., 2010). Recent functional magnetic resonance imaging
(fMRI) studies also show a lower activity level within the mPFC of individuals with
autism during a spatial working memory task (Luna et al., 2002). In addition, multi-voxel
pattern analyses following the employment of fMRI have shown that the functional
organization of the mPFC differs between those with and without autism (Gilbert et al.,
2009). Diffusion tensor imaging of cerebellar pathways in autistic children suggest a
reduced functional connectivity between the cerebellum and the cortex (Sivaswamy et al.,
2010). Also, autistic and cerebellar-damaged patients have impaired performance as
compared to controls on attention shifting tasks suggesting that abnormal functioning of
the cerebellum might be responsible for some of the cognitive impairments observed in
autism (Courchesne et al., 1994).
It is additionally noteworthy that dopamine release in the mPFC has been shown
to be associated with autism (Ernst, 1997), schizophrenia (Bennett, 1998), emotional
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processing (Morrow et al., 1999), and a variety of cognitive functions including attention,
working memory, and planning (Aalto et al., 2005; Gamo et al., 2010; Jackson and
Mogdahham, 2004; Rose et al., 2010). Associated with frontal lobe damage, autistic
patients also show deficits in representing their own or other’s mental states including
intentions, beliefs, wants and knowledge, abilities that have been collectively referred to
as ‘theory of mind’ (Bird et al., 2004). These indices of higher cognitive function appear
to be dependent on normal dopaminergic transmission in the mPFC (Lackner et al., 2010;
Montague et al., 2004). For example, positron emission tomography (PET) studies have
demonstrated that children with autism have reduced dopaminergic activity in the mPFC
(Ernst et al., 1997). Also, patients with heredodegenerative ataxias due to cerebellar
atrophy were found to have lower levels of homovanillic acid (HVA) in cerebrospinal
fluid (CSF) suggesting that overall dopamine concentrations are dependent on normal
cerebellar function (Botez and Young, 2001).
Using mice heterozygous for the lurcher spontaneous mutation (Grid2Lc), which
have almost total loss of cerebellar Purkinje cells (Caddy and Biscoe, 1979; Zuo et al.,
1997), and wildtype controls, we have recently shown that stimulation of the cerebellar
Purkinje cell layer and deep cerebellar dentate nucleus (DN) is able to evoke the release
of dopamine in the mPFC and that mPFC dopamine is dependent on functional cerebellar
Purkinje cell outputs (Mittleman et al., 2008). This is in agreement with the disconnection
hypothesis which posits that cognitive disorders like autism and schizophrenia result, at
least in part, in an interruption of neuronal circuitry between these cerebral and cerebellar
brain regions (Friston, 1999; Geshwind and Levitt, 2007). Thus, impaired connectivity
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between the cerebellum and mPFC could account for certain cognitive symptoms of
autism.
Cerebellar-modulation of mPFC dopamine release could be mediated by two
separate neuronal pathways originating in the DN, which serves as one of the principle
deep cerebellar output nuclei of the cerebellum (see Fig. 3 inset). The first is by indirect
activation of mesocortical dopaminergic neurons via contralateral projections of the DN
to reticulo-tegmental nuclei (RTN) that, in turn, project to pedunculopontine nuclei (PPT)
and then project to, and stimulate directly, ventral tegmental area (VTA) dopaminergic
cell bodies projecting to the mPFC (Forster and Blaha, 2003; Garcia-Rill et al., 2001;
Perciavalle et al., 1989; Schwarz and Schmitz, 1997; Snider et al., 1976). The second is
by activation of the contralateral projections of the DN to thalamic
mediodorsal/ventrolateral nuclei (ThN md/vl) that send efferents to the mPFC to
modulate mesocortical dopaminergic terminal release in the mPFC via appositional
excitatory glutamatergic synapses (Pinto et al., 2003; Del Arco and Mora, 2005;
Middleton and Strick, 2001).
The aim of the present study was to determine the neuronal pathways involved in
cerebellar modulation of mPFC dopamine release. To determine the relative contribution
of each candidate neuronal circuit in modulating mPFC dopamine release, we used fixed
potential amperometry in combination with carbon-fiber microelectrodes (Forster and
Blaha, 2003; Lester et al, 2008; Dickson et al, 2011) to monitor mPFC dopamine release
evoked by DN electrical stimulation before and during individual infusions of the local
anesthetic lidocaine, the ionotropic glutamate receptor antagonist kynurenate, and the
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control solution phosphate buffered saline (PBS) into the ThN md, ThN vl, or VTA of
urethane anesthetized lurcher wildtype mice.
MATERIALS AND METHODS
Subjects
The original stock of lurcher mice, B6CBACaAw-J/A-Grid2Lc, was obtained from
the Jackson Laboratory in Bar Harbor, Maine. Forty-five lurcher wildtype mice bred at
the University of Memphis were used in this study. The mice were housed five per cage
and were 10-14 weeks of age at the time of surgery. The mice were maintained at the
University of Memphis Animal Care Facility in a temperature controlled environment
(21.0±1.0 °C) on a 12h light: 12h dark cycle with food and water available ad libitum. All
experiments were approved by a local Institutional Animal Care and Use Committee and
conducted in accordance with the National Institutes of Health Guidelines for the Care
and Use of Laboratory Animals.
Surgery
Mice were anaesthetized with urethane (1.5g/kg, i.p.) and placed in a stereotaxic
frame with head-holder adaptor to ensure that the skull was level. Body temperature was
maintained at 36 ± 0.5º C with a temperature-regulated heating pad. Four holes were
drilled into the animals’ skulls to allow for the implantation of an Ag/AgCl
reference/auxiliary combination electrode, a carbon-fiber microelectrode (dopamine
recording electrode; carbon fiber 10 µm o.d., 250 µm length, Thornel Type P, Union
Carbide, PA; Forster and Blaha, 2003), a concentric bipolar stimulating electrode
(CBARD75, 125 µm outer and 25 µm inner pole diam., FHC, ME), and a 31g stainlesssteel guide cannula for drug microinfusions into appropriate nuclei. The Ag/AgCl
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reference/auxiliary combination electrode was placed contralateral to the recording
electrode which was placed in mPFC of the left hemisphere at a 30o lateral to medial
angle (coordinates from bregma: AP +2.35 mm, ML +1.0 mm, DV -1.5 mm from dura;
Paxinos and Franklin, 2001). The stimulating electrode was placed in the right DN
(coordinates from bregma: AP -6.24 mm, ML -2.1 mm, DV -2.25 mm from dura; Paxinos
and Franklin, 2001). The guide cannula tip was placed 1 mm above in the VTA, ThN md,
or ThN vl (coordinates from bregma: AP -3.3 mm, ML +0.35 mm, DV -3.0 mm from
dura; AP -1.35 mm, ML +0.4 mm, DV -2.75 mm from dura; AP -1.35 mm, ML +1.0 mm,
DV -3.45 mm from dura, respectively; Paxinos and Franklin, 2001).
Fixed Potential Amperometry and Electrical Stimulations
Immediately following electrode implantation, a constant voltage of +0.8 V was
applied to the recording electrode and oxidation current sampled continuously (10,000
samples/sec) via an electrometer (ED401 e-corder 401 and EA162 Picostat, eDAQ Inc.,
CO, USA) filtered at 50 Hz (Forster and Blaha, 2003). Electrical stimulation of the DN
consisted of 100 cathodic monophasic pulses (200-400 µA intensity, 0.5 ms pulse
duration) at 50 Hz every 60 seconds for a period of 10 to 15 minutes and were applied to
the stimulating electrode via an optical isolator and programmable pulse generator (IsoFlex/Master-8; AMPI, Jerusalem, Israel).
Pathway Inactivations
Following a baseline recording of at least 5 minutes, separate groups of mice
received microinfusions of lidocaine (0.02 µg), kynurenate (0.5 µg), or PBS. Infusions
were administered via the guide cannula. Drugs were first back-loaded into a fiberglass
infusion cannula (80 m o.d., Polymicro Tech. Inc., AZ, USA) and then connected via
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PE10 tubing to a 1.0 µl microsyringe (Scientific Glass Engineering, Inc., TX, USA). The
infusion cannula was then placed into the guide cannula to extend 1 mm from its tip into
the injection site. A 0.5 µl infusion of lidocaine, kynurenate, or PBS was then
administered over 1.0 min period and left in place. Changes in DN stimulation-evoked
dopamine oxidation current in the mPFC were recorded for 10 minutes post-infusion.
Data Analyses
The three DN stimulation-evoked responses immediately prior to each drug
infusion as well as the three responses immediately following infusion were extracted
from the continuous record and amperometric currents within the range of 0.2s prestimulation and 60s post-stimulation were normalized to zero current values. The currents
for each evoked response were then summed across time (-0.2s through 60s) for each
response due to dopamine concentrations significantly differing from pre-stimulation
baseline for several seconds post-stimulation (Mittleman et al., 2008). The relatively slow
recovery of the evoked dopamine signal to pre-stimulation baseline is consistent with the
paucity of dopamine transporters compared to the striatum (Sesack et al., 1998), a region
more densely innervated with dopaminergic neurons (Palkovits, 1979). As the preinfusion responses and the post-infusion responses were each one minute apart, two
repeated measures analyses of variance (ANOVA) were conducted with time (1-3) of
each pre-infusion response and time (1-3) of each post-infusion response, each as a
within-groups factor. For both analyses, site of infusion and drug administered were
between-group factors and the response sums at each time point were the dependent
variable. These analyses indicated that the stimulation-evoked responses did not differ
significantly across either pre-infusion or post-infusion times (F (2, 72) = 1.63, p = .203;
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F (2, 72) = .056, p = .945). Because the stimulation-evoked responses did not vary
significantly, the three pre-infusion response current sum values were averaged together
to compare with the average of the three post-infusion response current sum values. Thus,
the average percent post-infusion decrease was then obtained for each mouse with respect
to pre-infusion baseline responses (0%).
An ANOVA was then conducted using site of infusion (VTA, ThN md, or ThN
vl) and drug/vehicle infused (lidocaine, kynurenate, or PBS) as between-groups factors
and percent decrease of mPFC dopamine release as the dependent variable. If the
ANOVA indicated a significant interaction between site of infusion and drug infused,
Sidak-Bonferroni post-hoc comparisons were performed. Depending on the outcome of
the post-hoc tests, a series of t-tests with a Bonferroni correction were performed to
further identify significant differences.
Histology
Immediately following each experiment, a direct current (100 µA for 10 s; +5 V
for 5 sec) was passed through the stimulating electrode in the DN to leave iron deposits
and through the recording electrode in the mPFC to lesion tissue, respectively. Each
mouse was then euthanized with a lethal intracardial injection of urethane. The brains
were removed and preserved overnight in 10% buffered formalin containing 0.1%
potassium ferricyanide, and then stored in 30% sucrose/10% formalin solution until
sectioning. At the conclusion of the experiment, the brains were sectioned on a cryostat at
-30º C. A Prussian blue spot indicative of the redox reaction of ferricyanide and iron
deposits labeled the stimulating electrode tip in the DN, while placements of the
recording electrodes in the mPFC were determined by the position of the electrolytic
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lesion. Placements of the electrodes were confirmed under light microscopy and recorded
on representative coronal diagrams (Paxinos and Franklin, 2001).
RESULTS
Stereotaxic Placements of Electrodes
Figure 1 depicts the central placements of stimulating and recording electrodes
and infusion cannula tips. The stimulating electrode tips were confined within the DN (n
= 45 electrodes, ranging from, in mm, -6.1 to -6.35 AP, +1.9 to +2.2 ML, and -2.1 to -2.6
DV) posterior to bregma, lateral to midline, and ventral from dura. Infusion cannula tips
were confined to the ThN md (n = 15; ranging from in mm: -1.25 to -1.5 AP, +0.2 to +0.5
ML, and -2.45 to -2.95 DV), the ThN vl (n =15; ranging from in mm, -1.2 to -1.45 AP,
+0.9 to +1.2 ML, and -3.1 to -3.6 DV), and the VTA (n = 15; ranging from in mm: -3.1 to
-3.4 AP, +0.15 to +0.5 ML, and -3.7 to -4.25 DV) posterior to bregma, lateral to midline,
and ventral from dura. Recording electrode surfaces were confined within the mPFC (n =
45; ranging from in mm: +2.2 to +2.4 AP, +0.75 to +1.2 ML, and -1.9 to -2.1 DV)
anterior to bregma, lateral to midline and ventral from dura.
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Figure 1 Representative coronal sections illustrating placements (grey shaded areas) of
(A) stimulating electrodes in the dentate nucleus (DN), (B) dopamine recording
electrodes in the medial prefrontal cortex (mPFC), (C) infusion cannulae in mediodorsal
thalamus (ThN md) and ventrolateral thalamus (ThN vl), and (D) infusion cannulae in the
ventral tegmental area (VTA). Numbers correspond to mm from bregma. Dashed line in
(B) depicts the lateral to medial angle of recording electrode implantation. All stimulating
electrode and infusion cannulae were implanted vertically. Sections were adapted from
the mouse atlas of Franklin and Paxinos, 2001.
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Effects of Infusions on Stimulation-Evoked Dopamine Release in mPFC
Both lidocaine and kynurenate infusions at each of the injection sites achieved
their maximal inhibitory effects on DN stimulation-evoked dopamine release in the
mPFC within 1 min of infusion. Figure 2 shows individual examples of mPFC dopamine
release responses evoked by electrical stimulation of the DN, 3 min before and 3 min
after infusions of PBS into the VTA, and kynurenate or lidocaine into the ThN md. Prior
to kynurenate, lidocaine, or PBS infusions, DN stimulation-evoked an increase in
dopamine release with the signal peaking within ~5.5 seconds from the start of
stimulation and returning to pre-stimulation baseline within 50-60 seconds (Fig. 2 left
panels). A similar magnitude and time course in DN stimulation-evoked dopamine
release in the mPFC was observed following PBS infusion into the VTA (Fig. 2 top, right
panel). In contrast, DN stimulation-evoked release of mPFC dopamine was markedly
attenuated as shown in the examples of an intra-ThN md kynurenate and lidocaine
infusions with dopamine release peaking within ~2 to 5 seconds from the start of
stimulation and returning to pre-stimulation baseline within 20-30 seconds (Fig. 2 middle
and bottom, right panels). An ANOVA indicated a significant main effect for drug and
site of infusion (F (2, 36) = 65.53, p < .001; F (2, 36) = 28.53, p < .001, respectively) as
well as a significant interaction between drug and site of infusion (F (4, 36) = 6.04, p =
.001). Sidak-Bonferroni post-hoc comparisons indicated that the average percent decrease
of DN stimulation-evoked mPFC dopamine release in the three groups receiving PBS (M
= 1.9% ± 0.7%) did differ significantly from the average response of the groups receiving
either lidocaine or kynurenate. However, the average percent decrease of DN stimulationevoked mPFC dopamine release across all three groups receiving lidocaine (M = 34.2% ±
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4.8%) did not differ significantly from that of the three groups receiving kynurenate (M =
33.3% ± 4.5%).

Figure 2 Individual examples of medial prefrontal cortex dopamine release responses
evoked by electrical stimulation (black bar, 100 pulses at 50 Hz) of the dentate nucleus
(DN) 3 min before and 3 min after infusions of PBS into the ventral tegmental area
(VTA) and kynurenate into the mediodorsal thalamus (ThN md).
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A series of t-tests with Bonferroni correction for multiple comparisons indicated
that the percent decrease of mPFC dopamine release in each group following lidocaine or
kynurenate infusions into the VTA, ThN md, and ThN vl were significantly different than
the associated PBS controls (p < .008). In contrast, another series of t-tests with
Bonferroni correction indicated that the percent decrease of mPFC dopamine release in
each group following lidocaine was not significantly different than the kynurenate
infusions into the VTA, ThN md, and ThN vl (p > .05). As shown in Figure 3, the sitespecific average percent decrease for groups receiving lidocaine in the VTA, ThN md,
and ThN vl were 51.8% ± 6.9%, 35.6% ± 4.7%, and 15.2% ± 1.6%, respectively.
Similarly, kynurenate infusions resulted in comparable site-specific average percent
decreases of 49.2% ± 6.2%, 35.4% ± 4.4%, and 15.3% ± 2.4% for VTA, ThN md, and
ThN vl, respectively. In contrast, PBS infusions resulted in relatively minimal sitespecific average percent decreases of 2.8% ± 1.3%, 2.0% ± 1.1% and 0.8% ±1.3% for
VTA, ThN md, and ThN vl, respectively. As shown in Figure 3, the DN to mPFC
pathway via dopaminergic neuronal cell bodies in the VTA was decreased by either
lidocaine or kynurenate by ~50%, while the DN to mPFC via thalamic nuclei was also
decreased similarly by either lidocaine or kynurenate by ~50% (35% in the ThN md and
16% in the ThN vl). Thus, the sum of the percent decreases occurring in each of these
two pathways accounted for 100% of stimulation-evoked dopamine release recorded in
the mPFC.
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Figure 3 Average percent decrease in dentate nucleus (DN) stimulation-evoked
dopamine responses following lidocaine, kynurenate, or phosphate buffered saline (PBS,
control) infusions into the ventral tegmental area (VTA), mediodorsal thalamus (ThN
md), and the ventrolateral thalamus (ThN vl), as well as the summed average percent
decrease of each drug infused across sites. Infusions of kynurenate or lidocaine into the
VTA, ThN md, and ventrolateral thalamus (ThN vl) of separate groups of mice decreased
the dopamine response by approximately 50% (n = 15 and 15), 35% (n = 15 and 15), and
15% (n = 15 and 15), respectively while phosphate buffered saline (PBS, control) had no
significant effect in any group.
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DISCUSSION
The present results extend our previous findings that cerebellar or DN electrical
stimulation modulates mPFC dopamine release (Mittleman et al., 2008) by showing that
this modulation is dependent on two discrete and independent cerebellar to mPFC
neuronal circuits. Infusions of the local anesthetic lidocaine or the broad spectrum
ionotropic glutamate receptor antagonist kynurenate into the ThN md, ThN vl, or VTA
resulted in significant decreases in DN stimulation-evoked mPFC dopamine release,
compared to PBS control infusions in the same anatomical sites. Figure 3 (inset) shows
the underlying neuronal circuitry involved in deep cerebellar nuclei modulation of mPFC
dopamine release. Thus, one circuit utilizes a DN-RTN-PPT-VTA-mPFC circuit (Forster
and Blaha, 2003; Garcia-Rill et al., 2001; Schwarz and Schmitz, 1997) that involves
activation of mesocortical dopaminergic transmission at the level of dopaminergic cell
bodies in the VTA that synapse onto mPFC pyramidal neurons (Palkovits, 1979). In
addition, the present results also indicate that DN stimulation-evoked dopamine release in
the mPFC may alternatively utilize a DN-ThN md/vl-mPFC circuit (Pinto et al., 2003;
Middleton and Strick, 2001) that involves enhancement of mesocortical dopaminergic
transmission via appositional glutamatergic synapses with dopamine neuronal terminals
on mPFC pyramidal neurons (Del Arco and Mora, 2005). As such, these results provide
the first demonstration of glutamatergic modulation of mPFC dopamine release via the
cerebellar DN. The sum of the average percent decrease in mPFC dopamine release
following infusions into the two thalamic nuclei is approximately equivalent to the
decrease following infusions into the VTA suggesting that these two neuronal circuits
contribute equally to cerebellar mPFC dopamine modulation (see Fig. 3 inset). In
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addition, as the average percent decreases of dopamine release following either lidocaine
or kynurenate infusions in the VTA, ThN md and ThN vl summed to ~100%, it would
appear that cerebellar modulation of mPFC dopamine release may be wholly dependent
on these two neuronal circuits. Also, attenuations in DN stimulation-evoked mPFC
dopamine release in the groups receiving lidocaine and kynurenate were not significantly
different which suggests that inputs into the VTA and ThN md/vl that contribute to
mPFC dopamine release following DN stimulation are primarily, if not entirely,
glutamatergic.
Abnormal levels of dopamine in the prefrontal cortex have been found to be
associated with autism (Ernst et al. 1997), schizophrenia (Bennett, 1998), emotional
processing (Morrow et al., 1999), and cognitive functions (Brozoski et al., 1979). Our
finding of cerebellar modulation of dopamine in the PFC might thus provide a functional
explanation of cerebellar involvement in autism (Sivaswamy et al., 2010), schizophrenia
(Andreasen and Pierson, 2008), and other emotional and cognitive functions
(Schmahmann and Sherman, 1998; Stoodley, 2011). The equivalent participation of both
neuronal circuits, instead of only one, may offer a greater degree of flexibility in
cerebellar modulation of mPFC dopamine release, where an increase or decrease in
activity in one of these circuits may be compensated for by the other. As well, other
sources of inputs to subnuclei within a particular circuit, for example cortical and
subthalamic inputs to the PPT (Hammond et al., 1983; Parent and Hazrati, 1995), could
offer a means of fine tuning cerebellar outflow to the cortex and subsequent dopamine
release. Indeed, it is important to note that the thalamus is a critical relay-station of the
diencephalon through which nearly all sensory information is relayed to the cortex. It has
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input from striatum, globus pallidus, subthalamic nucleus, substantia nigra
compacta/76ransducer, and VTA. These inputs are integrated within the thalamus and
conveyed to the cortex which, in turn, provides positive feedback to the thalamus for
relevant input and suppresses irrelevant information (Da Cunha et al., 2009). The
involvement of thalamic circuitry, by which the cerebellum modulates cortical dopamine
release, would allow various inputs to the thalamus to modulate thalamic output to
provide a more precise modulation of cortical dopamine release. The present study
suggests that disconnections of cerebellar-mPFC circuitry, such as a reduction in the
number of cerebellar Purkinje cells leading to disruption of information outflow from
deep cerebellar nuclei, could result in aberrant dopaminergic activity in the mPFC. This
notion supports the autism disconnection hypothesis and provides a neuroanatomical
substrate via which the diversity of symptoms known to characterize autism could be
mediated (Geshwind and Levitt, 2007).
Functional Significance
Although this study did not address directly a loss of cerebellar Purkinje cells and
resulting behavioral consequences of such a loss, previous clinical and preclinical studies
suggest that cerebellar modulation of mPFC dopamine release is functionally relevant.
For example, several clinical functional imaging and lesion studies which support the
hypothesis that cerebellum and its reciprocal connections to the mPFC may contribute to
the implementation of many executive functions (Bracke-Tolkmitt et al., 1989;
Schmahmann and Sherman, 1998). In addition, using wildtype ↔ lurcher chimera mice
that exhibit varying Purkinje cell counts from 0 to 100%, we have previously shown that
a developmental loss of Purkinje cells can produce a decrease in reversal learning in mice
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(Dickson et al., 2010). The results of this recent study indicated that cerebellar Purkinje
cell number was directly correlated with impairments in behavioral flexibility in these
mice. We have also previously shown in lurcher chimera mice that a developmental loss
of Purkinje cells produces hyperactivity and repetitive behaviors as measured by activity
and investigatory nose-poking during open-field activity and hole-board exploration tests
(Martin et al., 2004, 2006, 2010; Dickson et al., 2010). Moreover, in rhesus monkeys
bilateral electrolytic lesions of the DN results in increased perseveration during a
conceptual set shifting task modeled after the Wisconsin card sorting task, suggesting that
the output of the cerebellum, and specifically the DN, is essential for executive function
mediated by the mPFC (Schmahmann et al., 2004). These executive function
impairments mimic those seen in individuals with autism suggesting that certain
cognitive deficits in autism are a result of aberrant dopaminergic activity due to a
disconnection of cerebellar-mPFC circuitry.
CONCLUSIONS
The present findings suggest that both DN-RTN-PPT-VTA-mPFC and DN-ThNmPFC neuronal circuitry contribute equally to cerebellar modulation of mPFC dopamine
release. Based on previous research, this modulation appears to have functional
relevance, such that the cerebellar Purkinje cell output modulates executive functions that
parallel those cognitive functions which are impaired in individuals with autism,
schizophrenia, and cerebellar cognitive affective syndrome. Our findings support the
disconnection hypothesis which purports that cognitive disorders like autism and
schizophrenia are due, at least in part, to reduced functional connectivity between brain
structures, including the cerebellum and prefrontal cortex (Friston, 1999; Geshwind and
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Levitt, 2007). In future studies it will be important to identify how these circuits might
compensate for a developmental loss of Purkinje cell output similar to that observed
clinically. This issue could be experimentally addressed using a mouse model of
varaiable Purkinje cell loss, such as lurcher chimeric mice, in order to determine how
Purkinje cell number influences dopamine release in the mPFC and glutamatergic
neurotransmission at different levels of cerebellar-mPFC circuitry. These studies would
provide more detailed information as to the relationship between neuropathologies of the
cerebellum and disruption of cerebellar-frontal cortex circuitry as well as suggesting
potential new targets for pharmacological intervention.
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Chapter 4
Examining Adaptations of Cerebellar-Cortical Circuitry in Mouse Models
with Developmental Cerebellar Damage Introduction
Autism is a neurodevelopmental disorder characterized by deficits in social skills
and communication, unusual and repetitive behavior, and deficits in cognitive function
(American Psychiatric Association, 2000). Although the etiology of autism is currently
unknown, heritability rates may be as high as 90%, and autism has been associated with
mutations of several genes (Bailey et al., 1995; Muhle et al., 2004). Mutations of the
Fragile X mental retardation 1 (FMR1) gene, for example, results in Fragile X Syndrome
(FXS), a developmental syndrome associated with multiple autism-like symptoms, and is
the most common monogenic cause of autism (Kaufmann et al., 2004).
Neuroanatomical abnormalities that could contribute to autism symptoms are
reported in multiple brain areas in autistic patients including the cerebellum and the
frontal cortex. The cerebellum, though traditionally thought to only be involved in motor
function, is now implicated in normal cognitive function (Schmahmann & Caplan, 2006).
The most common neural pathologies observed in autistic patients are cerebellar
hypoplasia and reduced Purkinje cell numbers (Bauman, 1991; Courchesne, 1997;
Courchesne et al., 1994; Courchesne et al., 1988; DiCicco-Bloom et al., 2006). The
frontal cortex is larger in individuals with autism, and increased volume of frontal lobe
cortex has been demonstrated to be positively correlated with autistic symptoms (Carper
& Courchesne, 2005; Kumar et al., 2010). These abnormalities of the frontal cortex may
be related to those of the cerebellum. In autistic patients, the degree of enlargement of the
frontal cortex is positively correlated with the degree of hypoplasia in the cerebellum
(Carper & Courchesne, 2000).
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We have recently examined two glutamatergic pathways originating in the
cerebellum and terminating in the prefrontal cortex that may explain this relationship
(Rogers et al., 2011). Both of these pathways originate in the cerebellar cortex and then
project to the deep cerebellar nuclei. The first then involves indirect activation of
mesocortical dopaminergic neurons via contralateral projections of the DN to reticulotegmental nuclei (RTN) that, in turn, project to pedunculopontine nuclei (PPT) and then
project to, and stimulate directly, ventral tegmental area (VTA) dopaminergic cell bodies
projecting to the medial PFC (mPFC; Forster & Blaha, 2003; Garcia-Rill et al., 2001;
Perciavalle et al., 1989; Schwarz & Schmitz, 1997; Snider et al., 1976). The second
involves activation of the contralateral projections of the DN to thalamic
mediodorsal/ventrolateral nuclei (ThN md/vl) that send efferents to the mPFC to
modulate mesocortical dopaminergic terminal release in the mPFC via appositional
excitatory glutamatergic synapses (Del Arco & Mora, 2005; Middleton & Strick, 2001;
Pinto et al., 2003; see Figure 2). It is possible that a loss of cerebellar input, such as the
Purkinje cell loss observed in autism, could lead to changes in these efferent pathways
and associated cognitive symptoms.
The aim of the present study was to evaluate adaptations of cerebello-cortical
circuitry following developmental cerebellar pathology in mice. To understand the
impact of cerebellar pathology on this circuitry, we used fixed potential amperometry
(FPA) in combination with carbon-fiber microelectrodes to monitor mPFC dopamine
release evoked by DN electrical stimulation before and during individual infusions of the
local anesthetic lidocaine, the ionotropic glutamate receptor antagonist kynurenate, and
the control solution phosphate buffered saline (PBS) into the ThN md, ThN vl, or VTA of
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urethane anesthetized mice. Wildtype mice and two mutant mouse strains with cerebellar
abnormalities were used. First, FMR1 mutant mice have an Fmr1tm1Cgr targeted mutation
display cerebellar abnormalities such as elongated Purkinje cell spines and decreased
volume of deep cerebellar nuclei (DCN; Ellegood et al., 2010; Koekkoek et al., 2005).
Second, lurcher mutant mice, while having no known genetic overlap with autism, have
nearly a complete loss of Purkinje cells between the 2nd and 4th weeks of life due to an
autosomal dominant mutation making these mice a useful model for exploring the impact
of the developmental Purkinje cell loss observed in autism (Caddy & Biscoe, 1979; Zuo
et al., 1997).
Materials and Methods
Animals
Experimental subjects were bred and maintained in the Animal Care Facility
located in the Department of Psychology at the University of Memphis. Mice were
continuously maintained in a temperature controlled environment (21±1ºC) on a 12:12
light:dark cycle (lights on at 0800) and were given free access to food and water. Original
lurcher (#001046) and Fmr1 breeders (#004624, #004828) were purchased from The
Jackson Laboratory (Bar Harbor, Maine).
Breeding
To produce lurcher mutant mice, ataxic male mice heterozygous for the lurcher
spontaneous mutation (B6CBACa Aw-J/A-Grid2Lc) were bred with non-ataxic female
wildtype mice (B6CBACa Aw-J/A-Grid2+). This breeding strategy produced litters
composed of both heterozygous mutant and wildtype mice. Two phases of breeding were
also required to produce Fmr1 mutant mice. In the first phase, male mice hemizygous for

89

the Fmr1tm1Cgr targeted mutation (FVB.129P2-Fmr1tm1Cgr/J) were bred with female
wildtype mice (FVB.129P2-Pde6b+ Tyrc-ch/AntJ). This breeding strategy produced litters
composed only of heterozygous females and wildtype males. In the second phase,
heterozygous female mice were bred with wildtype male mice to produce litters
containing both hemizygous and wildtype males which were subsequently used as
experimental subjects. Due to their ataxic gait, mice heterozygous for the lurcher
mutation are easily distinguishable from their non-ataxic wildtype littermates.
Genotyping of all Fmr1 mice used in present study was performed by Transnetyx
(Cordova, TN).
Surgery
Mice were anaesthetized with urethane (1.5g/kg, i.p.) and placed in a stereotaxic
frame with head-holder adaptor. Body temperature was maintained at 36 ± 0.5º C with a
temperature-regulated heating pad. Four holes were drilled into the animals’ skulls to
allow for the implantation of an Ag/AgCl reference/auxiliary combination electrode, a
carbon-fiber microelectrode (dopamine recording electrode; carbon fiber 10 µm o.d., 250
µm length, Thornel Type P, Union Carbide, PA; Forster & Blaha, 2003), a concentric
bipolar stimulating electrode (CBARD75, 125 µm outer and 25 µm inner pole diam.,
FHC, ME), and a 31g stainless-steel guide cannula for drug microinfusions into
appropriate nuclei. The Ag/AgCl reference/auxiliary combination electrode was placed at
the surface of the cortex and contralateral to the recording electrode which was placed in
mPFC of the left hemisphere at a 30o lateral to medial angle (coordinates from bregma:
AP +2.35 mm, ML +1.0 mm, DV -1.5 mm from dura; Paxinos & Franklin, 2001). The
stimulating electrode was placed in the right DN (coordinates from bregma: AP -6.24
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mm, ML -2.1 mm, DV -2.25 mm from dura; Paxinos & Franklin, 2001). The guide
cannula tip was placed 1 mm above in the VTA, ThN md, or ThN vl (coordinates from
bregma: AP -3.3 mm, ML +0.35 mm, DV -3.0 mm from dura; AP -1.35 mm, ML +0.4
mm, DV -2.75 mm from dura; AP -1.35 mm, ML +1.0 mm, DV -3.45 mm from dura,
respectively; Paxinos & Franklin, 2001).
Fixed potential amperometry and electrical stimulations
After implantation of all electrodes and cannulae, a constant voltage of +0.8 V
was applied to the recording electrode and oxidation current sampled continuously
(10,000 samples/sec) via an electrometer (ED401 e-corder 401 and EA162 Picostat,
eDAQ Inc., CO, USA) filtered at 10 Hz low pass (Forster & Blaha, 2003). Electrical
stimulation of the DN consisted of 100 cathodic monophasic pulses (800 µA intensity,
0.5 ms pulse duration) at 50 Hz every 60 seconds for a period of 10 to 15 minutes and
were applied to the stimulating electrode via an optical isolator and programmable pulse
generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel).
Pathway inactivations
Following approximately 5 minutes of baseline recording, separate groups of
mice received microinfusions of lidocaine (0.02 µg), kynurenate (0.5 µg), or PBS.
Infusions were administered via the guide cannula. Drugs were first back-loaded into a
fiberglass infusion cannula (80 m o.d., Polymicro Tech. Inc., AZ, USA) and then
connected via PE10 tubing to a 1.0 µl microsyringe (Scientific Glass Engineering, Inc.,
TX, USA). The infusion cannula was then placed into the guide cannula to extend 1 mm
from its tip into the injection site. A 0.5 µl infusion of lidocaine, kynurenate, or PBS was
then administered over 1.0 min period and left in place. Changes in DN stimulation-

91

evoked dopamine oxidation current in the mPFC were recorded for 10 minutes postinfusion.
Data analyses
The three DN stimulation-evoked responses immediately prior to each drug
infusion as well as the three responses immediately following infusion were extracted
from the continuous record and amperometric currents within the range of 0.2s prestimulation and 60s post-stimulation were normalized to zero current values. The currents
for each evoked response were then summed across time (-0.2s through 60s) for each
response due to dopamine concentrations significantly differing from pre-stimulation
baseline for several seconds post-stimulation (Mittleman et al., 2008). As the pre-infusion
responses and the post-infusion responses were each one minute apart, two repeated
measures analyses of variance (ANOVA) were conducted for each mouse genotype with
time (1-3) of each pre-infusion response and time (1-3) of each post-infusion response,
each as a within-groups factor. For all analyses, site of infusion and drug administered
were between-group factors and the response sums at each time point were the dependent
variable. These analyses indicated that the stimulation-evoked responses did not differ
significantly across either pre-infusion or post-infusion times (p > .05). Because the
stimulation-evoked responses did not vary significantly, the three pre-infusion response
current sum values were averaged together to compare with the average of the three postinfusion response current sum values. Thus, the average percent post-infusion decrease
was then obtained for each mouse with respect to pre-infusion baseline responses (0%).
An ANOVA was then conducted using site of infusion (VTA, ThN md, or ThN
vl) and drug/vehicle infused (lidocaine, kynurenate, or PBS) as between-groups factors
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and percent decrease of mPFC dopamine release as the dependent variable for each
mouse genotype. If the ANOVA indicated a significant interaction between site of
infusion and drug infused, Sidak-Bonferroni post-hoc comparisons were performed.
Depending on the outcome of the post-hoc tests, a series of t-tests with a Bonferroni
correction were performed to further identify significant differences.
Histology
Immediately following each experiment, a direct current (100 µA for 10 s; +5 V
for 5 sec) was passed through the stimulating electrode in the DN to leave iron deposits
and through the recording electrode in the mPFC to lesion tissue, respectively. Each
mouse was then euthanized with a lethal intracardial injection of urethane. The brains
were removed and preserved overnight in 10% buffered formalin containing 0.1%
potassium ferricyanide, and then stored in 30% sucrose/10% formalin solution until
sectioning. At the conclusion of the experiment, the brains were sectioned on a cryostat at
-30º C. A Prussian blue spot indicative of the redox reaction of ferricyanide and iron
deposits labeled the stimulating electrode tip in the DN, while placements of the
recording electrodes in the mPFC were determined by the position of the electrolytic
lesion. Placements of the electrodes were confirmed under light microscopy and recorded
on representative coronal diagrams (Paxinos & Franklin, 2001).
Results
Stereotaxic placements of electrodes
Figure 1 depicts the central placements of stimulating and recording electrodes
and infusion cannula tips in each mouse genotype. In all groups, the stimulating electrode
tips were confined within the DN (n = 144 electrodes, ranging from, in mm, -6.0 to -6.5
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AP, +1.7 to +2.7 ML, and -2.1 to -3.25 DV) posterior to bregma, lateral to midline, and
ventral from dura. Infusion cannula tips were confined to the ThN md (n = 48; ranging
from in mm: -1.05 to -1.45 AP, +0.15 to +0.7 ML, and -2.4 to -3.5 DV), the ThN vl (n
=48; ranging from in mm, -1.2 to -1.45 AP, +0.6 to +1.3 ML, and -3.1 to -3.95 DV), and
the VTA (n = 48; ranging from in mm: -3.1 to -3.3 AP, +0.15 to +0.55 ML, and -3.6 to 4.5 DV) posterior to bregma, lateral to midline, and ventral from dura. Recording
electrode surfaces were confined within the mPFC (n = 144;
ranging from in mm: +2.2 to +2.6 AP, +0.1 to +0.6 ML, and -0.8 to -1.55 DV) anterior to
bregma, lateral to midline and ventral from dura.
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Figure 1. Representative coronal sections illustrating placements (grey shaded areas) of (A) stimulating electrodes in the
dentate nucleus (DN), (B) dopamine recording electrodes in the medial prefrontal cortex (mPFC), (C) infusion cannulae in
mediodorsal thalamus (ThN md), (D) infusion cannulae in the ventrolateral thalamus (ThN vl), and (E) infusion cannulae in
the ventral tegmental area (VTA). Numbers correspond to mm from bregma. All stimulating electrode and infusion cannulae
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were implanted vertically while the dopamine recording electrode was implanted at a 45º
angle. Sections were adapted from the mouse atlas of Franklin and Paxinos, 2001.

Effects of infusions on stimulation-evoked dopamine release in mPFC
Both lidocaine and kynurenate infusions at each of the injection sites achieved
their maximal inhibitory effects on DN stimulation-evoked dopamine release in the
mPFC within 1 min of infusion. A series of ANOVAs indicated a significant main effect
for drug and site of infusion for each mouse genotype (lurcher mutant mice: F (2, 45) =
357.70, p < .001; F (2, 45) = 14.37, p < .001, respectively; FMR1 wildtype mice: F (2,
36) = 416.52, p < .001; F (2, 36) = 171.55, p < .001, respectively; FMR1 mutant mice: F
(2, 36) = 320.71, p < .001; F (2, 36) = 54.96, p < .001, respectively) as well as a
significant interaction between drug and site of infusion for each mouse genotype
(lurcher mutant mice: F (4, 45) = 4.261, p = .005; FMR1 wildtype mice: F (4, 36) =
34.78, p < .001; FMR1 mutant mice: F (4, 36) = 12.79, p < .001). Sidak-Bonferroni posthoc comparisons indicated that the average percent decrease of DN stimulation-evoked
mPFC dopamine release in all groups receiving PBS (lurcher mutant mice: M = 1.74% ±
0.60%; FMR1 wildtype mice: M = 1.23% ± 0.47%; FMR1 mutant mice: M = 1.21% ±
0.51%) did differ significantly from that of the associated groups receiving either
lidocaine or kynurenate. However, the average percent decrease of DN stimulationevoked mPFC dopamine release of each group receiving lidocaine (lurcher mutant mice:
M = 33.74% ± 1.68%; FMR1 wildtype mice: M = 32.61% ± 3.85%; FMR1 mutant mice:
M = 34.02% ± 2.63%) did not differ significantly from that of the groups of the same
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mouse genotype which received kynurenate (lurcher mutant mice: M = 32.97% ± 1.34%;
FMR1 wildtype mice: M = 32.93% ± 3.79%; FMR1 mutant mice: M = 33.54% ± 2.89%).

Table 1. Site specific percent decrease of mPFC dopamine release following intra-VTA,
ThN md, or ThN vl infusions of lidocaine, kynurenate, or PBS in FMR1 wildtype, FMR1
mutant, and FMR1 mutant mice.

FMR1 Wildtype
47.9% ± 3.4%
35.3% ± 1.5%
14.3% ± 1.0%

Mouse Genotype
FMR1 Mutant
21.5% ± 3.3%
41.6% ± 1.6%
38.9% ± 1.3%

Drug Infused
Lidocaine

Site of Infusion
VTA
ThNmd
ThNvl

Lurcher Mutant
29.3% ± 2.2%
31.1% ± 0.7%
40.8% ± 2.9%

Kynurenate

VTA
ThNmd
ThNvl

48.8% ± 1.3%
35.2% ± 1.7%
14.9% ± 0.5%

19.6% ± 1.2%
40.4% ± 3.4%
40.7% ± 1.4%

29.9% ± 1.7%
30.3% ± 1.4%
38.8% ± 1.9%

PBS

VTA
ThNmd
ThNvl

2.4% ± 0.9%
1.3% ± 0.8%
0.1% ± 0.4%

0.8% ± 0.8%
2.4% ± 0.9%
0.4% ± 0.8%

1.0% ± 0.9%
2.8% ± 0.8%
1.4% ± 1.3%

For all mouse genotypes, a series of t-tests with Bonferroni correction for multiple
comparisons indicated that the percent decrease of mPFC dopamine release in each group
following lidocaine or kynurenate infusions into the VTA, ThN md, and ThN vl were
significantly different than the associated PBS controls (p < .008). In contrast, another
series of t-tests with Bonferroni correction indicated that, for all mouse genotypes, the
percent decrease of mPFC dopamine release in each group following lidocaine was not
significantly different than the kynurenate infusions into the VTA, ThN md, and ThN vl
(p > .05). Table 1 shows the site-specific percent decrease following lidocaine,
kynurenate, or PBS in each mouse strain. mPFC dopamine release following PBS
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infusions into the VTA, ThN md, and ThN vl decreased less than 3.0% in all mouse
strains. As shown in Figure 2, mPFC dopamine release was decreased by either intraVTA lidocaine or kynurenate infusions by ~50%, while mPFC dopamine release was
decreased similarly by either intra-ThN lidocaine or kynurenate by ~50% (35% in the
ThN md and 15% in the ThN vl) in FMR1 wildtype mice. These results were very similar
to previously published results using the same procedure in lurcher wildtype mice
(Rogers et al., 2011). In lurcher wildtype mice, intra-VTA infusions of lidocaine or
kynurenate decreased mPFC dopamine release by ~50%, and intra-ThN infusions of
lidocaine or kynurenate also produced ~50% (~35% in the ThN md and ~16% in the ThN
vl) decrease in mPFC dopamine release (Rogers et al., 2011). In contrast, intra-VTA
infusions of lidocaine or kynurenate in FMR1 mutant mice resulted in ~20% decrease in
mPFC dopamine release, while intra-ThN infusions of either lidocaine or kynurenate
resulted in ~80% decrease (~40% in ThN md and ~40% in ThN vl) in dopamine release.
In lurcher mutant mice, intra-VTA infusions of lidocaine or kynurenate resulted in ~30%
decrease in mPFC dopamine release, while intra-ThN infusions of either lidocaine or
kynurenate resulted in ~70% decrease (~30% in ThN md and ~40% in ThN vl) in
dopamine release. In every mouse strain the sum of the percent decreases occurring in
each of these two pathways accounted for 100% of stimulation-evoked dopamine release
recorded in the mPFC.
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Figure 2. Average percent decrease in dentate nucleus (DN) stimulation-evoked dopamine responses following
lidocaine, kynurenate, or phosphate buffered saline (PBS, control) infusions into the ventral tegmental area (VTA),
mediodorsal thalamus (ThN md), and the ventrolateral thalamus (ThN vl), as well as the summed average percent decrease of
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each drug infused across sites. Dark blue bars represent Lurcher wildtype mice, red bars
represent Lurcher mutants, light blue bars represent FMR1 wildtype mice, and pink bars
represent FMR1 mutant mice.

Discussion
Autism is one of the most common neurodevelopmental disorders with an
unknown etiology and a lack of pharmacological treatment options. Understanding the
neuropathology underlying the disorder may provide pharmacological targets for the
treatment of autism. The current study aimed to understand the changes in cerebellocortical circuitry following the developmental loss of Purkinje cells that is typically
observed in autism. The present results support previous findings that the cerebellum
modulates mPFC dopamine release by two separate, glutamatergic pathways, the DNRTN-PPT-VTA-PFC and the DN-ThN md/vl-PFC pathway. The average percent
decrease of PFC dopamine release following lidocaine or kynurenate infusions into the
VTA, ThN md, or ThN vl did not significantly differ within each mouse genotype
suggesting that these pathways are primarily glutamatergic. Also, since infusions of
either lidocaine or kynurenate into the VTA, ThN md, and ThN vl summed to ~100%,
cerebellar modulation of mPFC dopamine seems to be unique to this circuitry.
These findings extend previous findings by showing that in mouse models of
autism with cerebellar abnormalities, the circuitry by which the cerebellum modulates
mPFC dopamine release is altered. In each of the wildtype strains (lurcher wildtype and
FMR1 wildtype), cerebellar modulation of mPFC dopamine is mediated equally by the
DN-RTN-PPT-VTA-PFC and the DN-ThN md/vl-PFC pathways. However, in both the
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lurcher mutant and FMR1 mutant strains, there is a shift in modulatory control to the
thalamic pathway. This shift may be the result of a loss of cerebellar output. Both the
lurcher mutant mouse and the FMR1 mutant mouse have been reported to have cerebellar
abnormalities that could impair cerebello-cortical connectivity. The Lurcher mutant
mouse displays a loss of nearly all Purkinje cells between the 2nd and 4th weeks of life due
to an autosomal dominant mutation (Caddy & Biscoe, 1979; Zuo et al., 1997). FMR1
mutant mice are reported to have more subtle cerebellar neuropathology including
elongated spines on cerebellar Purkinje cells and decreased volume of deep cerebellar
nuclei (Ellegood et al., 2010; Koekkoek et al., 2005). Despite having different cerebellar
abnormalities, both the lurcher mutant and FMR1 mutant mice display a similar
adaptation of cerebello-cortical circuitry with modulatory control of DN-stimulation
evoked PFC dopamine release shifting from the VTA to the thalamus in both mutant
strains.
Cognitive deficits are noted in the Lurcher and FMR1 mutant mice suggesting
that the changes in cerebello-cortical circuitry result in behavioral impairments in these
models. Because Lurcher mutants lose nearly all Purkinje cells, they are ataxic and
display characteristic jerking movements. Due to this, chimeric mice, which have a
variable loss of Purkinje cell dependent upon the incorporation of wildtype lineage, are
frequently used to examine the behavioral impact of Purkinje cell loss while eliminating
the confounding effects of motor impairment (Goldowitz et al., 1992). Lurcher mice and
chimeras display impaired behavioral flexibility as measured by a serial reversal learning
task, and learning errors were negatively correlated with the number of Purkinje cells in
subsequent cell counts (Dickson et al., 2010). Belzung and colleagues (2001) found that
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Lurcher mutant mice were impaired in object localization and radial arm maze tasks as
compared to controls suggesting memory deficits. Lurcher and chimeric mice also
display repetitive behaviors such as perseverative lever pressing, and this behavior was
found to be negatively correlated with Purkinje cell numbers (Martin et al., 2010). FMR1
mutant mice, which have elongated Purkinje cell spines and decreased volume of DCN,
display several behavioral deficits similar to those seen in autism (Bernardet & Crusio,
2006; Ellegood et al., 2010; Koekkoek et al., 2005). Bontekoe and colleagues (2002)
report that FMR1 knockout (KO) mice display hyperactivity and reduced fear
conditioning. FMR1 KO mice display perseverative behavior in that they have longer
latencies in reaching a platform in a swimming task after the position in changed
(D’Hooge et al., 1997; Kooy et al., 1996; The Dutch-Belgian Fragile-X Consortium,
1994). Baker and colleagues (2010) also report reduced spatial learning during place
navigation tasks and memory deficits during serial reversal tasks in FMR1 KO mice.
While a variety of insults can result in altered cerebellar development, the current
study suggests that a loss or impairment of cerebellar output affects downstream
cerebello-cortical circuitry. Changes in this circuitry, such as a shift of modulatory
control to the thalamus, could produce aberrant dopamine activity in the prefrontal cortex
and result in cognitive deficits such as those associated with autism. This is consistent
with the autism disconnection hypothesis which suggests that autism is the result of
impaired connectivity between two or more brain areas. Support for a loss or impairment
of cerebellar output and consequential changes in cerebello-cortical circuitry resulting in
the symptomology of autism patients comes from multiple sources.
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First, cerebellar pathology is associated with autism and autism spectrum
disorders as well as disorders with similar cognitive phenotypes. Cerebellar hypoplasia
and reduced cerebellar Purkinje cell numbers are the most consistent neural pathologies
linked to autism (Bauman, 1991; Courchesne, 1997; Courchesne et al., 1994; Courchesne
et al., 1988; DiCicco-Bloom et al., 2006). Postmortem studies report reductions in the
size and number of cells in the deep cerebellar nuclei in autistic patients (Bauman &
Kemper, 2005). Asperger’s syndrome has been associated with lower total cerebellar
volume and lower gray matter volume in the right cerebellum (Hallahan et al., 2009;
McKelvey et al., 1995; Yu et al., 2011). According to postmortem studies, patients with
Rett syndrome display reduced volume of the cerebellum, cerebellar atrophy, and
reduced Purkinje cell number (Murakami et al., 1992; Oldfors et al., 1990). Likewise,
cerebellar abnormalities such as ectopic Purkinje cells, focal cerebellar Purkinje cell loss,
and Bergmann gliosis are associated with Fragile X syndrome (Greco et al., 2011;
Sabaratnam et al., 2000).
Second, prefrontal cortex and thalamic abnormalities are found in patients with
autism and the degree of abnormality in these areas is correlated with severity of
symptoms suggesting that changes in cerebellar output affect downstream nuclei and
result in autistic symptoms. The frontal cortex is larger in individuals with autism, and
increased volume of frontal lobe cortex has been shown to be positively correlated with
autistic symptoms (Carper & Courchesne, 2005; Kumar et al., 2010). Importantly, the
degree of enlargement of the frontal cortex is also positively correlated with the degree of
hypoplasia in the cerebellum (Carper & Courchesne, 2000). While total brain volume is
positively correlated with the volume of the thalamus in control brains, a lack of
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correlation exists between total brain volume and volume of the thalamus in autistic
brains (Hardan et al., 2006; Tamura et al., 2010; Tsatsanis et al., 2003). The size of the
thalamus in autistic patients is reduced when compared to controls, and the size of the left
thalamus in children with ASD is inversely correlated with stereotypical and repetitive
behaviors (Estes et al., 2011; Tamura et al., 2010).
Third, abnormal levels of dopamine in the prefrontal cortex are associated with
autism and cognitive function deficits. A PET study found that autistic patients have
reduced dopaminergic activity in the PFC (Ernst et al., 1997). Lower levels of PFC
dopamine activity have also been associated with deficits to a variety of cognitive
functions including attention, working memory, and planning (Aalto et al., 2005; Gamo
et al., 2010; Jackson and Mogdahham, 2004; Rose et al., 2010).
While pre-clinical and clinical evidence suggests that the cerebellar pathology
observed in autism results in adaptations in cerebello-cortical circuitry and cognitive
deficits, it is unclear whether other neuropathologies in mouse models and autism
patients could contribute to cognitive symptoms.The specificity of developmental
damage occurring in the mouse models is not currently known, and autism patients also
display neuropathologies in multiple brain areas in addition to the cerebellum (Casanova,
2007). Therefore, future studies should attempt to determine the direct behavioral
consequences of developmental cerebellar pathology.
Conclusions
Pathologies of the cerebellum and frontal cortex are implicated in autism. We
have previously shown that the cerebellum modulates mPFC dopamine release via two
distinct glutamatergic pathways. The present study demonstrates that changes occur in
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cerebello-cortical circuitry following changes in cerebellar output. These findings
represent a possible explanation of the cognitive symptoms of autism and present new
pharmacological targets for the treatment of autism. Future studies should aim to
understand the direct consequences of cerebellar pathologies well as pharmacological
treatments to ameliorate behavioral deficits affiliated with cerebellar pathology.
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Chapter 5
Summary, Conclusions, and Implications for Future Research
While the etiology of autism remains unknown, recent basic and clinical research
heavily implicates the cerebellum in the disorder. The cerebellum is important for normal
cognitive function and cerebellar pathology has been associated with autism and a range
of cognitive disorders. Cerebellar hypoplasia and reduced Purkinje cell numbers are the
most common neural pathology noted in autism and are associated with ASD. Autistic
patients display abnormal activation of the cerebellum during certain tasks indicating
abnormal cerebellar function in this population. Multiple genes thought to contribute to
normal cerebellar development are associated with autism and ASD. Glutamatergic
cerebello-cortical circuitry, which modulates PFC dopamine release, is altered following
developmental cerebellar pathology in mice. Abnormalities of the cerebellum, changes in
cerebellar output, and subsequent effects on downstream circuitry might underlie and
thus explain some of the cognitive symptoms of autism. However, due to limitations of
clinical research, the direct effects of cerebellar pathology on downstream neuronal
circuitry and behavior are not yet known. The rodent models reviewed in Chapter 1
provide a way to further investigate the cerebellum’s role in autism. Rodent models of
autism both confirm often reported clinical findings and also extend these findings by
providing candidate pathways deserving of further research.
Neural circuitry mediating cerebellar modulation of mPFC dopamine release
The experiment in Chapter 3 extends previous findings that cerebellar or DN
electrical stimulation modulates mPFC dopamine release (Mittleman et al., 2008) by
showing that this modulation is dependent on two discrete and independent cerebellar to
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mPFC neuronal circuits. One circuit utilizes a DN-RTN-PPT-VTA-mPFC circuit
(Forster and Blaha, 2003; Garcia-Rill et al., 2001; Schwarz and Schmitz, 1997) that
involves activation of mesocortical dopaminergic transmission at the level of
dopaminergic cell bodies in the VTA that synapse onto mPFC pyramidal neurons
(Palkovits, 1979). The DN-ThN md/vl-mPFC circuit (Pinto et al., 2003; Middleton and
Strick, 2001) is also utilized in DN stimulation-evoked dopamine release in the mPFC
and involves enhancement of mesocortical dopaminergic transmission via appositional
glutamatergic synapses with dopamine neuronal terminals on mPFC pyramidal neurons
(Del Arco and Mora, 2005). As such, these results provide the first demonstration of
glutamatergic modulation of mPFC dopamine release via the cerebellar DN. The sum of
the average percent decrease in mPFC dopamine release following infusions into the two
thalamic nuclei is approximately equivalent to the decrease following infusions into the
VTA suggesting that these two neuronal circuits contribute equally to cerebellar mPFC
dopamine modulation. In addition, as the average percent decreases of dopamine release
following either lidocaine or kynurenate infusions in the VTA, ThN md and ThN vl
summed to ~100%, it would appear that cerebellar modulation of mPFC dopamine
release may be wholly dependent on these two neuronal circuits. Also, attenuations in
DN stimulation-evoked mPFC dopamine release in the groups receiving lidocaine and
kynurenate were not significantly different which suggests that inputs into the VTA and
ThN md/vl that contribute to mPFC dopamine release following DN stimulation are
primarily, if not entirely, glutamatergic.
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Adaptations in cerebello-cortical circuitry following developmental damage
The experiment described in Chapter 4 aimed to understand the changes in
cerebello-cortical circuitry following the developmental loss of Purkinje cells that is
typically observed in autism using two of the mouse models reviewed in Chapter 1: the
lurcher mutant mouse and the FMR1 mutant mouse. These results supported those
described in Chapter 3, and extended these findings by showing that in mouse models of
autism with cerebellar abnormalities, the circuitry by which the cerebellum modulates
mPFC dopamine release is altered. In each of the wildtype strains (lurcher wildtype and
FMR1 wildtype), cerebellar modulation of mPFC dopamine is mediated equally by the
DN-RTN-PPT-VTA-PFC and the DN-ThN md/vl-PFC pathways. However, in both the
lurcher mutant and FMR1 mutant strains, there is a shift in modulatory control to the
thalamic pathway. This shift may be the result of a loss of cerebellar output. Both the
lurcher mutant mouse and the FMR1 mutant mouse have been reported to have cerebellar
abnormalities that could impair cerebello-cortical connectivity. The Lurcher mutant
mouse displays a loss of nearly all Purkinje cells between the 2nd and 4th weeks of life due
to an autosomal dominant mutation (Caddy & Biscoe, 1979; Zuo et al., 1997). FMR1
mutant mice are reported to have more subtle cerebellar neuropathology including
elongated spines on cerebellar Purkinje cells and decreased volume of deep cerebellar
nuclei (Ellegood et al., 2010; Koekkoek et al., 2005). Despite having different cerebellar
abnormalities, both the lurcher mutant and FMR1 mutant mice display a similar
adaptation of cerebello-cortical circuitry with modulatory control of DN-stimulation
evoked PFC dopamine release shifting from the VTA to the thalamus in both mutant
strains.

117

In addition to cerebellar abnormalities, behavioral deficits are noted in the
Lurcher and FMR1 mutant mice suggesting that the changes in cerebello-cortical
circuitry result in cognitive deficits in these models. Lurcher mice display impaired
behavioral flexibility and repetitive behavior (Dickson et al., 2010; Martin et al., 2010).
FMR1 mutant display memory and learning deficits and hyperactivity (Baker et al., 2010;
Bontekoe et al., 2002). The consistent evidence of behavioral abnormalities in these mice,
and other mice with cerebellar abnormalities reviewed in Chapter 1, suggests that some
symptoms of autism can be explained by the cerebellar abnormalities commonly found in
these patients.
While a variety of insults can result in altered cerebellar development, the
experiment described in Chapter 4 suggests that a loss or impairment of cerebellar output
affects downstream cerebello-cortical circuitry. Changes in this circuitry, such as a shift
of modulatory control to the thalamus, could produce aberrant dopamine activity in the
prefrontal cortex and result in cognitive deficits such as those associated with autism.
This is consistent with the autism disconnection hypothesis which suggests that autism is
the result of impaired connectivity between two or more brain areas.
Recent clinical research supports the findings reported in Chapters 3 and 4 by
demonstrating that autistic patients not only have consistent cerebellar abnormalities but
PFC and thalamic abnormalities as well. The frontal cortex is larger in individuals with
autism, and increased volume of frontal lobe cortex has been shown to be positively
correlated with autistic symptoms (Carper & Courchesne, 2005; Kumar et al., 2010).
Importantly, the degree of enlargement of the frontal cortex is also positively correlated
with the degree of hypoplasia in the cerebellum (Carper & Courchesne, 2000). While
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total brain volume is positively correlated with the volume of the thalamus in control
brains, a lack of correlation exists between total brain volume and volume of the
thalamus in autistic brains (Hardan et al., 2006; Tamura et al., 2010; Tsatsanis et al.,
2003). The size of the thalamus in autistic patients is reduced when compared to controls,
and the size of the left thalamus in children with ASD is inversely correlated with
stereotypical and repetitive behaviors (Estes et al., 2011; Tamura et al., 2010). Indeed, it
is important to note that the thalamus is a critical relay-station of the diencephalon
through which nearly all sensory information is relayed to the cortex. It has input from
striatum, globus pallidus, subthalamic nucleus, substantia nigra compacta, and VTA.
These inputs are integrated within the thalamus and conveyed to the cortex which, in
turn, provides positive feedback to the thalamus for relevant input and suppresses
irrelevant information (Da Cunha et al., 2009). Therefore, the thalamus may be a target
for novel pharmaceutical treatments to ameliorate any behavioral impairments resulting
from its dysfunction.
Conclusions and Future Directions
Autism is one of the most common neurodevelopmental disorders with an
unknown etiology and a lack of pharmacological treatment options. Understanding the
neuropathology underlying the disorder may provide novel pharmacological targets for
the treatment of autism.The present findings suggest that both DN-RTN-PPT-VTAmPFC and DN-ThN-mPFC neuronal circuitry contribute equally to cerebellar modulation
of mPFC dopamine release. Basic research suggests that this modulation appears to have
functional relevance, such that the cerebellar Purkinje cell output modulates executive
functions that parallel those cognitive functions which are impaired in individuals with
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autism. Clinical research supports this notion since pathologies of the cerebellum and
frontal cortex are implicated in autism (Carper & Courchesne, 2005; Courchesne, 1997).
Overall these findings suggest that the cerebellum modulates mPFC dopamine release via
two distinct glutamatergic pathways and that changes occur in cerebello-cortical circuitry
following changes in cerebellar output. Our findings support the disconnection
hypothesis which purports that autism is due, at least in part, to reduced functional
connectivity between brain structures (Geshwind and Levitt, 2007). Specifically, these
results suggest that such a disconnection may occur within cerebello-cortical circuitry
resulting in aberrant mPFC dopamine activity thereby resulting in the cognitive
symptoms of autism.
Future research should aim to determine when during the developmental time
course the cerebellar lesions occur and the anatomical specificity of the cerebellar deficits
observed in the reviewed rodent models. Understanding the developmental timing and the
anatomical specificity of cerebellar pathology is important for understanding the causal
mechanisms underlying this consistent feature of autism. Understanding what
mechanisms prompt the developmental loss of Purkinje cells, for example, might lead to
methods of prevention or treatment of the neurochemical and behavioral consequences.
Ultimately, a better understanding of the direct effects of cerebellar pathology in autism
could lead to better diagnostic measures, earlier diagnosis, and novel pharmacological
targets for the treatment of autism and ASD.
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